...

2 0 0 9 – 2 0 1 0 ... Albert Einstein College of Medicine 1

by user

on
Category:

hats

106

views

Report

Comments

Transcript

2 0 0 9 – 2 0 1 0 ... Albert Einstein College of Medicine 1
2009–2010 Annual Report
Albert Einstein College of Medicine
o f y e s h i va u n i v e r s i t y
1
Albert Einstein College of Medicine is at the
forefront of bridging divides: between laboratory
breakthroughs and innovative therapies, between
disease and health, between lack of care and
compassionate care—all in the interest of
preventing illness and promoting healing.
“At Yeshiva University,
we must reaffirm
the aspiration of an
integrated life; an
aspiration for a life
of values, ideals and
meaning. We must
focus our efforts on
determining not what
we can take from the
world, but what we can
contribute to it.”
– Richar d M. J oe l
President, Yeshiva University
science to medicine
bri dg i n g t he di vi de
Letter from the Dean 10
Letter from the Chair 11
Bridging the Cardiovascular Divide 12
Bridging the Translational Divide 18
Bridging the Health-Care Divide in the Bronx
32
Bridging the Student-to-M.D. Divide 38
Bridging the Global Health-Care Divide 44
Bridging the Practitioner-Researcher Divide 52
Our Supporters 58
ON THE COVER: Left, Naomi Maria assists in the Einstein laboratory of John S. Condeelis, Ph.D.;
right, Leo Lopez, M.D., works with a young heart patient at The Children’s Hospital at Montefiore.
2
A new liver can mean the difference between imminent
death and decades more of life. Accurately predicting that
breast cancer will not spread could spare women treatment
that is costly, exhausting and unnecessary. Understanding
how cells die during heart attacks and their aftermath can
reveal strategies for keeping cells alive. Einstein researchers
are identifying new ways to combat disease and improve
health by turning laboratory discoveries into new treatments
for patients in our community and throughout the world.
Because we are
making a difference.
Milan Kinkhabwala, M.D., is chief of
transplantation at Montefiore Medical
Center, the University Hospital
and Academic Medical Center for
Einstein. Bronx patients may soon
benefit from an alternative to liver
transplants known as cell therapy.
It involves injecting stem cells or
healthy liver cells to replace damaged
liver tissue. Cell therapy pioneer
Sanjeev Gupta, M.D., the Eleazar and
Feige Reicher Chair in Translational
Medicine at Einstein, predicts that it
will be done here in the near future.
2
3
From diabetes to drug addiction, daunting health
challenges confront Bronx residents, many of whom are
poor and medically underserved. Albert Einstein College
of Medicine—the borough’s only medical school—takes
its responsibility to be a good neighbor seriously. From a
new and comprehensive cancer prevention program to an
innovative effort that recruits minority students for healthcare careers, Einstein is serving the Bronx community in
many different ways.
Because it is
our home.
Bronx resident Ismael Santos with
his twin 16-year-old daughters,
Janine, left, and Janice, who have
cerebral palsy. The family has
received treatment and support
at the Children’s Evaluation and
Rehabilitation Center on the
Einstein campus since the girls
were 6 months old. “We’ve had
the same team of excellent doctors
all these years,” says Mr. Santos.
“All the therapies my daughters
need are here.”
4
5
Beyond our neighborhood and nation, people are suffering
from diseases that are treatable or preventable. Einstein
scientists partner with colleagues and institutions worldwide to alleviate this suffering and improve lives. One of
these Einstein initiatives is in Uganda, where children are
succumbing to malnutrition diabetes, a lethal and littleunderstood disease. Other Einstein clinicians are working
on better ways to treat drug-resistant tuberculosis and to
prevent the transmission of AIDS.
Because it is
our mission.
The photo at right was taken last
August in Kampala, Uganda, during
a two-and-a-half–day diabetes
conference organized by Einstein’s
Meredith A. Hawkins, M.D. The
College of Medicine sponsors
numerous initiatives worldwide,
including clinical and research
programs in Argentina, Bangladesh,
Brazil, Ethiopia, Guatemala, India,
Nigeria, Rwanda, South Africa,
Uganda and Vietnam.
6
7
What will health care in the United States look like 10 or 20
years from now? Will all Americans have access to the care
they need? Will breakthroughs minimize the death toll from
heart disease and cancer? The answers aren’t known, but the
students and scientists who will influence them are right here
on the Einstein campus. As they look to the future, they will
also be grounded in the traditions—compassion, collegiality,
humanism and the zealous pursuit of knowledge—that have
made Einstein a premier institution where leadership in
medical education and research advances go hand in hand.
Because we are
the future.
Cara Chrisman, a graduate student
who assists in the lab of Arturo
Casadevall, M.D., Ph.D., the Leo
and Julia Forchheimer Professor
of Microbiology & Immunology,
will graduate this spring. She may
then pursue a postdoctoral degree
or go into scientific policy-making
or science writing—all doors that
are open to her thanks to her
Einstein education. Cara also serves
in several student government
organizations and has received the
Graduate Student Council’s Student
Service Award.
8
9
letters from
the dean
the chair
“In theory, there is no difference between theory and
practice. In practice, there is.”
When I became chairperson of the Board of Overseers of Albert Einstein
College of Medicine in 2007, I was very excited about the vision projected
by our (then) new dean, Allen Spiegel, and the goals that he, together with
the Einstein faculty and administration, set for the medical school.
Two and a half years later, this team has achieved several key goals and
is on course to accomplish many others. They range from exciting new
research in areas such as heart disease and cancer, to the recruitment of
new faculty, to the expansion of Einstein’s work overseas—all described
in this Annual Report. I think I can speak for the entire Board of Overseers
when I say that we are all thrilled and proud to be part of the Einstein
community.
From the time Einstein was created, the brilliance, dedication and
collegiality of its faculty have been legendary. Now these scientists are
pressing forward, intent on seeing their discoveries result in the cure or
elimination of diseases that besiege us all. Always a giant in basic research,
Einstein continues to develop new ways to translate its findings to meet
challenges to the health of people across the globe.
Einstein has long been a leader in medical education and insists on
providing the latest and most timely training to make today’s medical
students the compassionate and expert physicians of the future. Our
students gain a wealth of experience serving the health needs of people
from myriad backgrounds in the Bronx and New York City, as well as in
underserved areas in many countries around the world.
Einstein’s continued excellence in research and education is possible
thanks to the philanthropic investments of our friends and alumni. On
behalf of the entire Einstein community and our dedicated Board of
Overseers, let me express our most sincere appreciation to everyone
whose generosity makes the mission of Einstein possible.
– Y og i Berra
Allen M. Spiegel, M.D.
The Marilyn and
Stanley M. Katz Dean
In the quote above, the legendary Yankee catcher was probably distinguishing between the advice offered to a hitter by his batting coach and
the batter’s actual experience trying to hit a 95-mile-per-hour fastball. As it
turns out, Yogi’s aphorism aptly describes what is known as the translational
block: the divide between obtaining meaningful laboratory findings and
putting them into practice in the “real world.” This year’s Annual Report is
all about bridging that divide.
Robust and sustained support for research is critically important,
enabling investigators to make discoveries that address the many unmet
challenges in medicine. But research results alone do not translate
into improved health. For example, completion of the human genome
sequence in 2000, while certainly a landmark achievement, will not by itself
usher in an era of genomic, personalized medicine. Likewise, meaningful
health-care reform, by which I mean achieving universal access to quality
care at an affordable and sustainable cost, will not by itself eliminate health
disparities in our own country, much less resolve the global health problem
of neglected diseases.
Bridging the divide between research and practice requires new ways of
teaching our students to practice the medicine of the future and new ways
of training the clinical investigators who move research results from the lab
to the clinic. Overcoming health disparities and addressing global health
challenges require new models for community-based research and care,
locally in our own Bronx neighborhoods and globally in developing countries. Translating research results into new methods of diagnosing, treating
and preventing disease—and then merging those advances into routine
practice—requires new types of research partnerships among basic scientists, epidemiologists, clinical investigators and community practitioners.
This year’s Annual Report clearly illustrates the many ways in which
Einstein is successfully bridging the divide in each of these areas. Einstein
faculty and students can take pride in the significant accomplishments
described in these pages. To our many supporters—members of the
Einstein Board of Overseers, our alumni, foundations, corporations, our
Women’s and Men’s Divisions, and our many other donors who recognize
Einstein’s unique commitment to scientific excellence and humanism—
I offer sincere gratitude.
Ruth l. Gottesman, Ed.D.
Chair, Einstein
Board of Overseers
Sincerely,
Ruth L. Gottesman, Ed.D.
Chair, Einstein Board of Overseers
Allen M. Spiegel, M.D.
The Marilyn and Stanley M. Katz Dean
10
11
Bridging the Cardiovascular Divide
“Heart” is at the center of the Einstein motto,
“science at the heart of medicine.” Now,
heart research is the focus of the new Wilf
Family Cardiovascular Research Institute,
made possible by a generous gift from a
distinguished philanthropic family with a
talent for teamwork.
Einstein researchers have traditionally tackled
medicine’s toughest challenges, and cardiovascular
disease certainly qualifies: it’s the world’s leading
cause of death. Over the years, Einstein has generated
landmark advances in cardiovascular research. Recently,
a multidisciplinary team of cardiovascular experts led
by Richard N. Kitsis, M.D., the Dr. Gerald and Myra
Dorros Professor of Cardiovascular Disease, has built
on that strong foundation.
And now, thanks to a $10 million gift from Einstein
Overseer Zygmunt Wilf and his family, Dr. Kitsis will
expand the ranks of Einstein’s already stellar cardiovascular research team. The Wilfs’ remarkable gift
will establish the Wilf Family Cardiovascular Research
Institute at Einstein—and greatly help in closing
the gap between cardiovascular disease and
cardiovascular health.
Einstein experts at the new institute will work to
understand, prevent and treat heart attack, stroke,
heart failure, hypertension, arrhythmias, sudden cardiac
death, congenital heart disease and many other conditions affecting the heart and blood vessels. The investigators will probe why heart disease is not the same for
women as for men. They’ll explore how the heart and
blood vessels are affected by obesity, atherosclerosis,
high cholesterol and abnormal blood lipids. And they’ll
study areas of great promise such as cardiac stem cells,
which may one day help replace heart muscle cells that
die during heart attacks and heart failure.
This vitally important new institute at Einstein would
not have been possible without Mr. Wilf, a leading supporter of the College of Medicine who is well versed in
the art of team building.
12
Wilf Team Spirit Creates a New Home for
Cardiovascular Research at Einstein
Collaboration—key to many successful enterprises and
a hallmark of medical research at Einstein—has played
a pivotal role in the life of Einstein Overseer Zygmunt
“Zygi” Wilf. Mr. Wilf hails from a family of leading
New York–area philanthropists.
“I learned from my dad and my Uncle Harry that
philanthropy allows our family to use our time and
resources to help those in need,” explains Mr. Wilf,
who is an active supporter of numerous Jewish and
other charitable organizations.
In 2003, Mr. Wilf and his wife, Audrey, became
Benefactors of Albert Einstein College of Medicine.
That same year, Mr. Wilf joined Einstein’s Board of
Overseers and now serves as a vice chairperson.
“My involvement with the medical school is extremely
rewarding,” he says. “It helps me understand how our
family’s support can advance Einstein’s mission—to
improve human health through medical research and
discovery. It’s very fulfilling to know we can make
a difference.”
His zest for life and for taking on tough challenges,
along with lessons learned from his family about the
value of hard work, perseverance and the Jewish
tenet of tikkun olam (“repair of the world”)—all drive
Partners in advancing cardiovascular research, left to
right: Jonathan Wilf and fiancée Rachel Goodman,
Audrey Wilf, Richard N. Kitsis, M.D., Joseph Wilf, Dean
Allen M. Spiegel, M.D., Zygmunt “Zygi” Wilf, Elizabeth
Wilf, Leonard Wilf and Mark Wilf, at the Einstein Faculty
Club, October 12, 2009.
Zygi Wilf’s philanthropic vision. They explain, in part,
his family’s decision to donate $10 million to establish
the Wilf Family Cardiovascular Research Institute
at Einstein.
Born in Germany in 1950, Zygi Wilf emigrated to
the United States in the early 1950s with his parents,
Joseph and Elizabeth Wilf, both Holocaust survivors.
The family settled in New Jersey.
Mr. Wilf learned about teamwork early in life by
watching his father and his late uncle, Harry Wilf,
build—virtually from the ground up—a highly successful real estate development business, Garden Homes
and Garden Commercial Properties. After briefly practicing law, Zygi Wilf joined the family business. He is
now president of Garden Commercial Properties.
An avid sports fan, Mr. Wilf fulfilled a childhood
dream in 2005 when he became a principal owner of
the Minnesota Vikings football team, leading a group
of investors that includes his brother, Mark, and his
cousin Leonard Wilf. Soon after he assumed ownership
13
of the Vikings, a New York Times story noted that
he “won over fans and players by swiftly addressing
significant issues.”
”The owner has to be there for the players and
for the staff, and it’s important they see you have the
passion for what they’re doing,” said Mr. Wilf in
describing his role with the Vikings.
The same holds true for Mr. Wilf’s role as an
investor in Einstein. His family’s gift will have a significant impact on advancing cardiovascular research at
the College of Medicine, and he has great respect for
the researchers carrying it out, chief among them
Richard N. Kitsis, M.D.
Choosing the Director
Zygi Wilf with Minnesota Vikings star defensive end
Jared Allen (photo courtesy of Minnesota Vikings).
“Medical research can be slow and
painstaking, and it requires great
resolve and tenacity to be successful.
Collaboration with others and the
support of an exceptional partner
and quintessential team builder like
Zygi Wilf can be indispensable.”
– Richar d N. K i ts i s , M . D .
The Dr. Gerald and Myra Dorros Professor
of Cardiovascular Disease
Director, Wilf Family Cardiovascular
Research Institute
14
Dr. Kitsis, the Einstein physician-scientist tapped to
become director of the new Wilf Family Cardiovascular 14
Research Institute, is eminently qualified for the job. A
professor in the departments of medicine (cardiology)
and cell biology, Dr. Kitsis is an internationally recognized expert on cell death. He came to Einstein in 1989
as a postdoctoral fellow in microbiology & immunology following clinical training in internal medicine and
cardiology. Dr. Kitsis was formally invested as director
of the Wilf Family Cardiovascular Research Institute at
Einstein’s Academic Convocation in October 2009.
To devote his time to developing and leading the
new institute, Dr. Kitsis chose to step down as chief of
cardiology at Einstein and Montefiore Medical Center.
He has begun hiring for the cardiovascular institute,
which ultimately will be staffed by more than 40 physicians and researchers.
Building the Team
Einstein has a long tradition of excellence in
cardiovascular research. Among the giants in the field
who have worked at the College of Medicine was the
late Edmund H. Sonnenblick, M.D., chief of the division
of cardiology from 1975 to 1996. Dr. Sonnenblick
launched modern cardiology when he recognized that
the heart is a muscle and behaves like one; his research
also helped lead the way to angiotensin-converting
enzyme (ACE) inhibitors—one of the main classes of
antihypertensive drugs.
One of Dr. Sonnenblick’s colleagues, Leslie A.
Leinwand, Ph.D., a molecular biologist at Einstein in the
1980s and early 1990s and a professor in the departments of microbiology & immunology, genetics and
medicine, was a founder of the field of molecular cardiology—the cornerstone of basic cardiovascular research
today. Dr. Kitsis’ desire to pursue cardiovascular
research was sparked by the work of Dr. Leinwand,
who became his mentor.
Not surprisingly, the Wilf Family Cardiovascular
Research Institute will be home to clinicians who
specialize in heart problems—pediatric cardiologists
and cardiothoracic surgeons, for example. But in
addition, there will be scientists from the 11 basic
science departments at Einstein as well as specialists in
medical areas including endocrinology, radiology and
nuclear medicine. Population scientists will be recruited
from the department of epidemiology & population
health at Einstein.
“We’ll be working on understanding, diagnosing
and treating cardiovascular disease from a broad perspective,” says Dr. Kitsis. He notes that heart disease,
stroke and other cardiovascular problems can result
from defects, deficits and faulty connections affecting
many different organs, tissues and cells. To understand
these problems requires contributions from a diverse
group of basic scientists, clinical scientists and population scientists.
Cultivating a Collaborative
Research Environment
The Wilf Family Cardiovascular Research Institute will
emphasize interdisciplinary programs—a growing
trend in biomedicine. “The tradition of collaboration
at Einstein is extraordinary, and we’d like to further
The most basic decision that any cell can make is to
divide, differentiate or die. Dr. Kitsis’ laboratory studies
how and why cells die and how cell death influences
health and disease. At left, Richard N. Kitsis, M.D.,
and cardiology fellow Lina Restrepo, M.D.
expand it to help translate research into clinical practice,” says Dr. Kitsis. “As institute director, I will be
making sure that researchers and clinicians from different specialties cross paths and cross-pollinate. In time,
I expect they’ll reach out to one another on their own.
Just imagine the multiplicative effects we can achieve!”
In addition to carrying out his duties as director, Dr.
Kitsis will continue his own research. “I am interested
in the most fundamental mechanisms that determine
if a cell lives or dies,” he says. Why this “morbid
obsession,” as Allen M. Spiegel, M.D., the Marilyn
and Stanley M. Katz Dean, humorously described it
when honoring Dr. Kitsis at Convocation? “Because
understanding how to keep cells alive requires that we
understand the mechanisms through which cells die,”
says Dr. Kitsis.
One form of cell death, called apoptosis, has
already been widely explored and is largely understood. It turns out that other, poorly understood celldeath processes are operating as well. “We are trying
to create a ‘wiring diagram’ to explain how these
various death processes integrate,” Dr. Kitsis says.
He notes that cell death processes have important
15
Needs retouching:
its distinguished support; the University named its
Washington Heights campus the Wilf Campus in 2002,
in recognition of the family’s philanthropic leadership.
In 2007, Joseph Wilf, together with other Wilf family
members and YU staff, began to consider ways to build
on the Wilf-Yeshiva partnership. After careful study and
evaluation by Zygi Wilf, the family determined that
Einstein—the first medical school in America established under Jewish auspices—would be an appropriate
new focus for its philanthropy.
Two years later, in 2009, the Wilf family announced
its most recent commitment: $25 million to Yeshiva
University, of which $15 million was designated for YU
undergraduate scholarships and $10 million to establish
the Wilf Family Cardiovascular Research Institute
at Einstein.
The Wilf family’s extraordinary gift is a testament to
the vision and foresight of Joseph Wilf and his loved
ones, and to the special bond that exists between a
remarkable family and the institution whose mission
they have embraced as their own.
The institute will support research into congenital
cardiovascular defects. At right, Daphne T. Hsu, M.D.,
professor in the department of pediatrics at Einstein
and codirector of the Pediatric Heart Center at
The Children’s Hospital at Montefiore, tends to a
young heart patient.
implications, ranging from normal life processes to
heart attacks, stroke, cancer and diabetes. “A true
understanding of this fundamental area of biology
will tell us a lot about ourselves and how we evolved,”
says Dr. Kitsis. “Moreover, this information will probably provide opportunities to devise new therapies
for the most common and lethal diseases.
“Sometimes even a modest advance may be of
great help to an individual who is suffering,” he adds.
The ultimate goal of the Wilf Family Cardiovascular
Research Institute, he says, is “to translate biological
understanding into novel treatments to relieve
suffering and improve health.”
Gifts such as the Wilf family’s, says Dean Spiegel,
“allow Einstein faculty to go forward doing the work
they love, that they are passionate about and that
will benefit the community and the world.”
16
Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz
Dean, presents Zygi Wilf with a plaque recognizing the
Wilf family and their gift establishing the Wilf Family
Cardiovascular Research Institute at Einstein. “Thanks to
the extraordinary vision and generosity of Zygi Wilf and
his family, Einstein will have a new institute targeting the
number-one killer of Americans,” says Dean Spiegel.
A Unique and Enduring Relationship
For nearly 40 years, the name Wilf has been closely
linked with that of Yeshiva University. The University’s
main campus bears the name of this distinguished
philanthropic family, which for decades has been a
pillar of the Jewish community from New York to Israel
and beyond. Joseph Wilf, the family’s patriarch, and
his son Zygi are longtime members of the YU Board
of Trustees.
Now entering its third generation of support for
YU, this singular clan proudly embodies the American
dream. Joseph Wilf, his wife, Elizabeth, and his
brother, Harry, survived the Holocaust, transplanted
themselves in America and went on to create a
thriving business. Each phase of their odyssey was
guided by their strongly held values: love of family,
passionate commitment to strengthening the Jewish
community and concern for humanity.
They identified Yeshiva University as the perfect
conduit to give expression to their values and began
investing in scholarships to support the development
of new generations of Jewish leaders. Thus began
the special relationship between the Wilf family and
the first American Jewish university. The family long
ago attained Benefactor status at the University for
“Success, whether in business, in sports
or in medical research, usually doesn’t
happen without teamwork. It takes a
dedicated team to make important
medical discoveries. The Wilf family’s
relationship to Einstein is more than a
partnership—we’re playing on the same
team. Together, we’re going to achieve
great things.”
left - 125 / right - 403 + 135 side
– Zygmu nt ”Zygi“ Wilf
Einstein Overseer and Benefactor
“The Wilf family is a shining example of YU’s mission to
ennoble and enable,” says Yeshiva University President
Richard M. Joel, pictured here with Zygi Wilf. ”Quietly
performing their good deeds under the radar, never
seeking publicity, the Wilfs have had a profound impact
on the growth and development of the University and on
the advancement of the Jewish people and humanity.”
17
Bridging the Translational divide
Typically, many years elapse before laboratory
findings culminate in useful therapies. The aim
of translational research is to shorten that time
lag—to build bridges between basic and clinical research that will speed knowledge “from
bench to bedside.” All across the Einstein
campus, translational research collaborations
are paving the way for new therapies that
will benefit patients as quickly as possible.
It starts right here, on the Einstein campus: A physicianscientist finds that transplanted liver cells survive longer
when pretreated with a certain drug, or a researcher
observes cancer cells moving from tumors to blood
vessels for the first time. But from there, where?
At Einstein, such basic research findings are fasttracked from the lab and onto a developmental speedway that transforms them into diagnostic tests or
therapies to improve human health. This emphasis on
moving from science to medicine is what translational
medicine is all about. “Every advance in medical care
that you’ve ever heard of—all of the important steps
in treating heart disease, cancer, diabetes and other
major medical challenges—came from basic research in
places like Einstein,” says Harry Shamoon, M.D., associate dean for clinical and translational research and director of the Einstein-Montefiore Institute for Clinical and
Translational Research (ICTR).
It usually takes a team effort to shepherd a basic
research discovery all the way to clinical practice.
Fortunately, collegiality and collaboration—two traditional strengths at Einstein—have resulted in a number
of translational medicine success stories.
18
Einstein’s Commitment to
Translational Medicine
The College of Medicine has reached some notable
benchmarks in translational medicine in the past
decade.
2001: Renowned investment fund manager
Michael F. Price committed $25 million to help establish a state-of-the-art center for genetic and translational medicine at Einstein.
2006: Allen M. Spiegel, M.D., became Einstein’s
Marilyn and Stanley M. Katz Dean after a distinguished
career at the National Institutes of Health (NIH), where
translational research is strongly encouraged.
2007: Dean Spiegel issued the Strategic Research
Plan, which made translational research at Einstein
a priority: “Basic science research remains the main
engine for discovery and innovation,” the dean wrote
in his introduction to the plan, “but translation of basic
science discoveries to benefit human health is critical if
the public’s investment in research is to be sustained.”
2008: The Michael F. Price Center for Genetic
and Translational Medicine/Harold and Muriel Block
Research Pavilion was formally dedicated, and the NIH
granted a coveted Clinical and Translational Science
Award to Einstein and to Montefiore Medical Center.
The five-year, $24 million grant supported the new
ICTR. “Researchers and clinicians don’t necessarily
Biochemist Matthew Levy, Ph.D., left, and endocrinologist
Daniel Stein, M.D., center, entered a collaborative
relationship when ICTR director Harry Shamoon, M.D.,
suggested they pool their expertise. Dr. Stein’s knowledge of thyroid tumor biology and Dr. Levy’s skill with
aptamers, the nucleic-acid equivalent of antibodies, will
form the basis of a new thyroid cancer test.
speak the same language,” said Dr. Shamoon. The
ICTR’s mandate was to act as matchmaker, bringing
together people who could catalyze each other’s work.
2009: Dean Spiegel signed an affiliation agreement with Steven M. Safyer, M.D., president and
chief executive officer of Montefiore, ensuring that
the research partnership between the two institutions, dating from the 1960s, would continue for the
next decade. “By combining Einstein’s strengths in
translational research and technical expertise with
Montefiore’s stellar reputation in patient care and clinical investigation, the agreement helps to ensure that
collaborations will flow smoothly,” said Dean Spiegel.
In addition, said Dr. Shamoon, “faculty members can
now see the scientific expertise and research projects
available at Einstein in real time on our website [www.
einstein.yu.edu/ERP]. This offers investigators an easy
way to make research connections.”
19
Detecting Breast Cancer’s Spread
Einstein Chairperson Emeritus Burton P. Resnick, right, and Judith Resnick with John S. Condeelis, Ph.D.
Collaborating
to Combat Cancer
Burton and Judith Resnick’s major gifts have played a vital
role in important medical advances at Einstein—past,
present and future.
Cancer. Dr. Condeelis, inaugural holder of the Judith
and Burton P. Resnick Chair in Translational Research, is an
internationally recognized microscopist and cell biologist.
Dr. Condeelis’ pioneering investigations into the way cancer
spreads hold major implications for cancer treatment. (See
pages 21-22 to learn more about Dr. Condeelis and his work.)
Alzheimer’s disease. A research team led by Peter
Davies, Ph.D., the Judith and Burton P. Resnick Professor of
Alzheimer’s Disease Research, identified a key missing protein
in the brains of Alzheimer’s patients—a breakthrough that has
influenced all subsequent Alzheimer’s disease research.
Leukemia. The Judith and Burton P. Resnick Chair in Cell
Biology is currently held by Arthur Skoultchi, Ph.D., chair and
professor in the department of cell biology. Dr. Skoultchi has
identified a gene that causes red blood cells to stop developing and to multiply uncontrollably. His work could lead to new
therapies for the treatment and prevention of leukemia.
20
A few years ago, John S. Condeelis, Ph.D., codirector of Einstein’s Gruss Lipper Biophotonics Center, was
looking at his laser-illuminated videos of living breast
tumor tissue when he observed something amazing:
cancer metastasis in action. Cells from the tumor were
on the move, migrating toward clumps of white cells,
known as macrophages, perched on blood vessels. The
macrophages seemed to be luring the motile tumor
cells toward them.
In metastasis, cancer cells spread from the primary
tumor and travel in the bloodstream to other parts of
the body, where they develop into secondary tumors.
This phase of cancer is arguably the most crucial, since
metastasis is what usually kills cancer patients. But to
actually witness metastasis was unprecedented.
“People had never seen cancer cells move to blood
vessels before,” says Dr. Condeelis, a breast cancer
researcher who is professor and cochair in the department of anatomy and structural biology.
The microscopic region where blood vessels, tumor
cells and macrophages interact is called “the tumor
microenvironment.” The notion that this microenvironment spawns metastasis was recently called “the hottest
idea in cancer research.” In their pioneering microenvironment research, Dr. Condeelis and his team are
deciphering the chemical signals that transform stationary tumor cells into motile metastatic killers. They hope
to develop therapies for blocking those signals so that
metastasis can be prevented or halted.
Partnering with Distinguished
Einstein Benefactors
In 2009, Dr. Condeelis’ groundbreaking studies were
brought to the attention of Judith and Burton P. Resnick,
longtime Benefactors of the College of Medicine.
The Resnicks are deeply committed to Einstein.
Mr. Resnick served with great distinction as chairman of
the Einstein Board of Overseers for 18 years and is now
actively involved as chairperson emeritus. Mrs. Resnick
has long been a leading member of Einstein’s National
Women’s Division.
The couple were so impressed with Dr. Condeelis’
work that they established the Judith and Burton P.
Resnick Chair in Translational Research at the College of
Medicine. On October 12, 2009, the Resnicks took part
in the Academic Convocation held on Einstein’s Jack
and Pearl Resnick Campus, during which Dr. Condeelis
was invested as the inaugural holder of the new chair.
Using an advanced imaging system like the one shown
above in his laboratory, Dr. Condeelis was able to see
cancer metastasis occurring in living tissue.
“Through their steadfast leadership
and philanthropic vision, Burt and
Judy Resnick have helped set the
stage for groundbreaking scientific
discovery at Einstein.”
– A llen M. S piegel, M.D.
The Marilyn and Stanley M. Katz Dean
21
T h e Breast Ca n cer R esearch
F o u nd at i o n
The Breast Cancer Research Foundation
has contributed $732,554 to support three
separate studies in breast cancer research
being conducted by: Rachel Hazan, Ph.D.,
associate professor, department of pathology;
Thomas Rohan, M.D., Ph.D., professor
and chair, department of epidemiology &
population health; and Susan Band Horwitz,
Ph.D., the Rose C. Falkenstein Professor of
Cancer Research and distinguished professor,
departments of molecular pharmacology
and of cell biology, and Haley McDaid, Ph.D.,
assistant professor, department of medicine.
Gabr ie l le ’ s A nge l F o u n dat i o n
fo r C a ncer R esearch
The Gabrielle’s Angel Foundation for Cancer
Research (formerly the G&P Foundation for
Cancer Research) has committed $225,000
to help fund the research of Amit Kumar
Verma, M.B., B.S., into myelodysplastic
syndrome, a disease of the bone marrow
that is increasingly common in older people
and often leads to leukemia. Dr. Verma is an
associate professor, department of medicine.
Su san G . K o me n f o r t he Cure
A grant of $180,000 from Susan G. Komen
for the Cure will support the work of Nancy
Carrasco, M.D., on a novel approach to breast
cancer treatment that combines radioiodide
and pyruvate. Dr. Carrasco is a professor in
the department of molecular pharmacology.
M ary K ay A s h C har i tab le
F o u nd at i o n
The Mary Kay Ash Charitable Foundation has
pledged $100,000 to support the work of
Ekaterina Dadachova, Ph.D., the Sylvia and
Robert S. Olnick Faculty Scholar in Cancer
Research. Dr. Dadachova is exploring radiolabeled antibodies as a novel approach to
treating cervical cancer. Collaborating with
Dr. Dadachova in these studies is Arturo
Casadevall, M.D., Ph.D., the Leo and Julia
Forchheimer Professor and chair, department
of microbiology & immunology.
“We’re fortunate to live in an era of medical
advances that our parents could only dream about,”
observes Mr. Resnick. “Judy and I are interested in
results. After meeting with Dr. Condeelis and learning firsthand about the rapid progress he and his
team are making in shedding light on metastasis, we
were convinced. We decided to help ensure that the
resources are there to keep the momentum going for
Dr. Condeelis and for future Einstein investigators.”
Predicting the Spread of Breast Cancer
As his research progressed, Dr. Condeelis found evidence for what he called a tumor microenvironment
for metastasis, or TMEM, a location where three types
of cells are present: endothelial cells (which form the
inner lining of blood vessels); perivascular macrophages
(a type of immune cell found near blood vessels); and
tumor cells that produce a protein called Mena (which
enhances a cancer cell’s invasiveness).
The more TMEMs in a tumor specimen, Dr.
Condeelis predicted, the greater the likelihood that
metastasis would occur. His prediction was confirmed
in a study published in the April 2009 issue of Clinical
Cancer Research.
In this study, Dr. Condeelis collaborated with pathologists at NewYork-Presbyterian Hospital in examining
60 breast tissue biopsy samples: 30 from patients with
advanced metastatic cancer and 30 from patients with
localized breast cancer. The researchers had developed a tissue test that used dye-carrying antibodies to
stain all three cellular components of a TMEM, thereby
revealing the presence and density of TMEMs in
the samples.
The resulting immunostains were evaluated by two
pathologists who were not aware of the patients’ clinical
outcomes. Their analysis confirmed that TMEM density
was significantly higher in patients who had developed
metastatic cancer than in those who had localized
disease.
“TMEM is the first marker that reliably predicts
whether a tumor is likely to metastasize,” says Dr.
Condeelis. He notes that the test could rule out
exhausting and expensive chemotherapy or radiation
for women whose tumors are not destined to metastasize, and could save the lives of other women by
correctly identifying metastatic disease. Dr. Condeelis
and his colleagues are now working on a blood test that
would measure the same markers and that might be
available in five years.
New Women’s Division
Initiative Supports Research
in Women’s Cancers
The National Women’s Division of Albert Einstein
College of Medicine has launched a fundraising
initiative to support research on women’s health and
cancers. The division seeks to raise $3 million over
the next three years for cutting-edge basic and translational studies focusing on cancers that specifically
affect women, including breast cancer and gynecological (ovarian, cervical and uterine) cancers.
Leading scientists from virtually all disciplines and
academic departments at Einstein who are members
of the Albert Einstein Cancer Center are conducting
the collaborative research studies that will benefit from
the new initiative. Under the leadership of I. David
Goldman, M.D., the Susan Resnick Fisher Professor
and director of the Cancer Center, the investigators
are working to find new and innovative treatments,
prevention strategies and, ultimately, cures for women’s cancers. They hope to develop personalized
treatments that will eliminate the need for patients
to undergo therapies that may be unnecessary or
ineffective.
The National Women’s Division has raised millions in support of medical research and education
programs at Einstein since 1953. Above right, top:
left to right, Jackie Harris Hochberg, president of the
New York chapter; Denise Rothberg, president of the
Westchester/Fairfield chapter; and Kathy Weinberg,
president of the National Women’s Division.
Above right, bottom: At the division’s annual Spirit
of Achievement luncheon on April 28, left to right,
Spirit honoree Robert W. Marion, M.D., director of the
Children’s Evaluation and Rehabilitation Center; Marcia
Galan, whose daughter, Alena, receives services from
CERC; Einstein Overseer Rita Rosen, former National
Women’s Division president, current board chair of the
division’s Westchester/Fairfield chapter and a board
member of its New York chapter; Alena Galan; and
Bambi Felberbaum, immediate past president of the
National Women’s Division. Above left: Young participants in the division’s 20th Annual Family Day “Wild,
Wild West Carnival,” held on August 9. The popular
event is attended each year by families who summer
in the Hamptons.
22
23
New Liver, New Life
Photo coming today
S t u de n t P rofile:
A le xan dra O go r o d n ik ova
Obesity tends to increase the risk for a
slew of health problems. But not always.
“Some obese people don’t have the
complications we expect to see, such as
diabetes, heart disease and hypertension,”
says Alexandra Ogorodnikova (above,
at right), the first student enrolled in the
ICTR’s new five-year Ph.D. track in clinical
investigation. “I’m looking into why these
obese people stay healthy.”
Now in her third year of the program,
Alexandra is working on epidemiologic
research projects with Rachel P. Wildman,
Ph.D. (at left above), associate professor
in the department of epidemiology &
population health.
“Learning how certain obese individuals
manage to avoid health problems may allow
us to help the general obese population,” says
Alexandra. “Our goal is to find interventions
for obese patients who develop diabetes,
heart disease and other complications that
increase their risk for heart attack and stroke.”
In her free time, Alexandra maintains her
own cardiac health by participating in the
Einstein Dance Club.
24
In the autumn of 2008, the first liver transplant program
in the Bronx opened at Montefiore Medical Center—
part of a collaboration between Montefiore and the
Einstein Liver Center. “We’ve done 11 transplants since
then,” says Milan Kinkhabwala, M.D., chief of transplantation and director of abdominal organ transplantation
at Montefiore. The program has special significance
for the Bronx, a region with one of the nation’s highest
rates of cirrhosis, hepatitis and other liver diseases.
Soon it may be possible to treat liver disorders without replacing the entire organ, thanks to the efforts of
Sanjeev Gupta, M.D., the first Eleazar and Feige Reicher
Chair in Translational Medicine and professor of medicine and of pathology. Dr. Gupta is pioneering efforts to
treat liver disease through “cell therapy”—transplanting
stem cells or other cells that multiply and restore lost or
diseased tissue.
Coming soon to the Bronx is a cell therapy technique in which healthy liver cells are separated from
donor livers and then injected into patients’ livers.
“We’re now transplanting liver cells into animals and
trying to understand how these cells become a part of
the body, grow, and take over the function of diseased
liver cells,” says Dr. Gupta. “We’re also looking at what
drugs or other treatments would encourage liver cells
to engraft and proliferate. Over the last 10 or 15 years
we’ve established a research base and can now begin
approaching clinical studies.”
Dr. Gupta is optimistic that Einstein and Montefiore
may perform their first human liver cell transplants in the
near future. However, because cell therapy is regulated
by the U.S. Food and Drug Administration, “we will
need to develop the necessary procedures for generating suitable cells, banking them, characterizing them,
and understanding whether they’re viable, safe and
effective,” he notes.
Meanwhile, Dr. Gupta is also developing strategies for turning human embryonic stem cells into fully
functional liver cells that could be transplanted into the
body—no liver donor required.
Translational research is usually assumed to run
just in one direction—from the laboratory to the clinic.
But as Dr. Kinkhabwala observes, findings from the
clinic can provide important information for laboratory
researchers. For example, he notes, “We recently set
up a tissue-banking protocol so that basic scientists
can access diseased liver tissue—or whole livers—from
surgical specimens for molecular analysis.”
Reicher Estate
Bestows Generous
Gift on Einstein
The College of Medicine has received a $10.2 million bequest
from the estate of Gertrude E. Reicher in memory of Eleazar
and Feige Reicher.
A portion of this remarkable gift has been used to endow
the Eleazar and Feige Reicher Chair in Translational Medicine,
named for the parents of the late Jacob Reicher, M.D., who
was interested in medical research. The inaugural holder of
the Reicher Chair is Sanjeev Gupta, M.D., professor in the
departments of medicine and of pathology and program
director for translational technologies and resources at
Einstein’s Institute for Clinical and Translational Research. This
honor recognizes Dr. Gupta for his leading role in the field of
regenerative medicine (see facing page).
Another portion of the Reicher bequest has been used
to help renovate the Gruss Magnetic Resonance Research
Center at Einstein (see page 29).
“The Reicher bequest exemplifies the selflessness of
philanthropically minded individuals who, knowing they
will not receive recognition in their lifetimes, simply wish
to leave the world a better place,” said Allen M. Spiegel,
M.D., Einstein’s dean. “Einstein is fortunate to be the beneficiary of this extraordinarily generous gift, which will have a
significant impact on key areas of biomedical research.”
25
“Carol and I are very pleased to help
Einstein realize the enormous potential
of translational research. It’s great to have
the opportunity to serve on the Einstein
Board and continue the good work my
parents started so many years ago.”
– Ro ger einiger
Ei n ste i n Ove rse e r
Roger and Carol Einiger: A Family
Tradition of Service to Einstein
Comes Full Circle
At right, R. Suzanne Zukin, Ph.D., with S. Dillard Kirby,
executive director of the F. M. Kirby Foundation, at the
Academic Convocation, October 12, 2009.
T h e M c K n ig ht E n do wmen t
F u n d f or Ne ur o sci e n ce
The McKnight Endowment Fund for
Neuroscience has awarded $300,000 over
three years to Dr. Zukin in support of her
research, in collaboration with John Greally,
M.B., B.Ch., Ph.D., associate professor of
genetics and of medicine, into epigenetic
remodeling of neuronal genes in global ischemia. The goal of this research is to pave the
way for innovative treatments to ameliorate
the effects of stroke.
26
F. M. Kirby Foundation Endows Chair in
Neural Repair and Protection
“History demonstrates time and time again that when
people are united in a charitable cause, which is right
and good, the impossible becomes possible.” These
inspirational words are from the mission statement of
the F. M. Kirby Foundation. The venerable family foundation has been a longtime supporter of neurological
research at Einstein.
Most recently, the foundation pledged $2 million
to endow the F. M. Kirby Chair in Neural Repair and
Protection. The inaugural holder of the Kirby Chair is
R. Suzanne Zukin, Ph.D., professor in the Dominick P.
Purpura Department of Neuroscience and director of
Einstein’s Neuropsychopharmacology Center.
During her 30-year career at Einstein, Dr. Zukin has
carried out pioneering research on the receptors on
the surface of nerve cells to which the neurotransmitter
glutamate binds. Her work has helped reveal how these
receptors are involved in medical conditions such as
schizophrenia, Huntington’s disease and stroke.
In 2001, the foundation established the F. M. Kirby
Program in Neural Repair and Protection at Einstein’s
Rose F. Kennedy University Center for Excellence in
Developmental Disabilities Education, Research and
Service. That gift was preceded by a generous contribution from the foundation in support of the neuroscience
program based at the Kennedy Center.
“Our family has always been committed to supporting
medical research because of its power to transform so
many lives,” says Einstein Overseer Roger Einiger. Mr.
Einiger joined the Einstein Board of Overseers in 2005.
He currently serves as the Board’s treasurer, chair of the
budget and finance committee and a member of the
executive committee.
In 2008, he joined the finance and investment
committees of the Yeshiva University Board of Trustees.
The University recognized Mr. Einiger for his dedicated
service by awarding him an honorary Doctor of Humane
Letters degree at its annual Hanukkah Dinner in
December 2009.
The Einiger family’s involvement with Einstein began
with Mr. Einiger’s parents, Glory and Jack, who were
among the medical school’s earliest supporters and
members of its Society of Founders. Glory Einiger also
played a leadership role in Einstein’s National Women’s
Division until her husband died suddenly in 1964. The
responsibilities of raising two children and running her
late husband’s business forced Mrs. Einiger to cut back
on her volunteer activities at Einstein. “For me,” says
Roger Einiger, “it’s been great to reconnect with
Einstein decades later and see the enormous progress
that has been made.”
Although Einstein receives funding from the NIH,
additional support is needed to fully fund the training
of Einstein’s research physicians. Recognizing this critical
need, Mr. Einiger and his wife, Carol, recently made a
commitment to support the career development of
physician-scientists—clinically trained M.D.s who are
involved in translational research studies.
The Einigers’ support for translational research at
Einstein will help advance the work of physicianscientists such as Amy Sanders, M.D., right, a geriatric
neurologist who studies cognitive aging. Dr. Sanders
is assistant professor in the Saul R. Korey Department
of Neurology.
The Elli so n Med ical
Foundati o n
The Ellison Medical Foundation continues to
recognize the outstanding accomplishments
of Einstein faculty members in aging
research. The foundation’s most recent
commitment is an award of up to $982,000
to support the work of Aviv Bergman, Ph.D.,
professor and founding chair, department
of systems & computational biology and
professor of pathology and of neuroscience.
Other current recipients of multiyear grants
include Jan Vijg, Ph.D., chair and professor,
department of genetics; Claire Bastie, Ph.D.,
assistant professor, department of medicine
(endocrinology); Marion Schmidt, Ph.D.,
assistant professor, department of biochemistry; and Erik Snapp, Ph.D., assistant
professor, department of anatomy and
structural biology.
27
Combating Infertility
The female sex hormone progesterone creates the
right chemical environment for a fertilized ovum to
be implanted in a woman’s uterus. “Without it there
would be no life,” notes Jeffrey W. Pollard, Ph.D.,
the Louis Goldstein Swan Chair in Women’s Cancer
Research and professor in the departments of developmental and molecular biology and of obstetrics &
gynecology and women’s health.
“We’ve made major advances in understanding how the actions of hormones
contribute to diseases of the uterus.”
But progesterone serves another useful purpose.
The hormone estrogen stimulates division of endometrial cells that line the uterus. Progesterone, because it
neutralizes estrogen, helps rein in endometriosis—the
wild and often painful proliferation of endometrial cells
outside the uterus that causes scarring and can lead
to infertility. Progesterone also helps combat uterine
cancer, another estrogen-fueled disorder. The most
effective treatment is hysterectomy, which leaves a
woman unable to bear children.
“Over the last five years, we’ve made major
advances in understanding how the actions of
28
Jeffrey W. Pollard, Ph.D., the Louis Goldstein
Swan Chair in Women’s Cancer Research, assisted
by laboratory technician Lumie Benard.
hormones contribute to uterine cancer and other diseases of the uterus,” says Dr. Pollard. For the first time,
Dr. Pollard and colleagues are studying the opposing
effects of progesterone and estrogen in living human
tissue by implanting human endometrial cells in mice.
These studies have revealed two new molecular pathways through which estrogen delivers its hormonal
message telling endometrial cells to divide. Armed
with this knowledge, scientists may be able to interrupt estrogen’s message earlier in the disease process
or develop an alternative to progesterone, which
becomes ineffective over time.
Because of these advances, the NIH in 2009
awarded Dr. Pollard a $7.5 million grant to create a
Specialized Cooperative Center Program in Reproduction and Infertility Research at Einstein—one of just
13 such centers funded nationwide and the only one in
New York State. The grant supports the translation of
lab breakthroughs into clinical practice and laboratory
follow-up on questions that arise in the clinic.
Researchers at Dr. Pollard’s new center will also
investigate the mechanisms by which obesity and
diabetes cause infertility in women. This research will
be especially relevant to Einstein’s Bronx community,
where obesity and diabetes are prevalent.
From Bedside to Bench at Gruss MRRC
Two scientists could hardly be better suited to
collaborate than Craig A. Branch, Ph.D., and
Michael L. Lipton, M.D., Ph.D.
Dr. Branch directs the Gruss Magnetic Resonance
Research Center (MRRC) and is a magnetic resonance
imaging (MRI) physicist. Dr. Lipton, the center’s
associate director, is a physician. “We bring two points
of view to the work,” says Dr. Branch.
In a twist on the usual bench-to-bedside direction
of translational research, studies in the Gruss Center
typically start with clinical mysteries in need of
scientific explanation. Take head injuries, for example.
“A standard MRI may show nothing abnormal, but
there’s clearly something wrong—maybe the person
can’t do his job or interact with people the way he
did,” says Dr. Lipton. In 2009, Drs. Branch and Lipton
and their colleagues published a study of concussion
patients in the journal Radiology. The study used a
new imaging technique, diffusion tensor imaging
(DTI), that measures the diffusion of water in the
brain’s white matter.
“DTI proved to be a powerful tool for detecting
subtle brain damage associated with concussions,”
says Dr. Lipton, who is also an associate professor of
radiology and of psychiatry and behavioral sciences
at Einstein. Adds Dr. Branch, “For the first time, we
appear to be able to provide researchers with a
Pictured above at the Gruss Magnetic Resonance
Research Center: Einstein Overseer Evelyn Lipper, M.D.
’71, with Michael Lipton, M.D., Ph.D., left, and Craig
Branch, Ph.D. Dr. Lipper, an Einstein alumna and former
faculty member, is a trustee of the Gruss Lipper Family
Foundation, which established the center in 2000 with a
generous gift to Einstein. “Drs. Lipton and Branch are a
dynamic team,” says Dr. Lipper. “Their vast breadth of
knowledge and vision for the future will greatly amplify
the Gruss Center’s impact on biomedical research and
on the education of Einstein students.”
target for therapies to reduce or eliminate the damage
of concussion.”
In addition to head injury, research at the Gruss
Center involves areas as diverse as cancer, cardiology, diabetes, obesity and hematology. The center’s
imaging capabilities got a big boost in June, when
a brand-new 3.0 Tesla MRI and spectroscopy system
was hoisted from a truck in the Einstein courtyard
and gently lowered into its new home on the first
floor. “Instead of scanning from the usual two points,
our new system allows us to use a technology called
parallel imaging that picks up signals from 32 different
sensors,” says Dr. Branch, who is also an associate professor of radiology at Einstein. “These images reveal
much greater detail than we’ve been able to attain
previously, and in half the time.”
29
“Jack Rudin gives with an open hand, but he is
also discerning,” says Dr. Norman Lamm, chancellor
of Yeshiva University, which in 1995 awarded Mr. Rudin
an honorary doctorate in recognition of his longstanding friendship and support. “When it comes
to Einstein,” says Dr. Lamm of his friend of many
years, “Mr. Rudin is greatly impressed with how
hard the students work. Knowing that the fruits of
their labor will benefit humanity is very important
to him.”
Samuel G. and Kathy Weinberg:
A history of Service to Einstein
Jack Rudin chats with Rudin Scholars Dukagjin Blakaj,
M.D., Ph.D.’08, left, and Lisa McReynolds, M.D., Ph.D. ’09,
at a 2006 reception honoring Mr. Rudin.
Saluting Jack Rudin and the
Rudin Family Foundations
Jack Rudin loves young people, and he loves the field
of medicine. So it’s no wonder that he has taken a
keen interest in supporting the medical education of
Einstein students.
Mr. Rudin is chairman of the Rudin Management
Company, one of New York City’s leading real estate
firms. He also serves as chairman of the May and
Samuel Rudin Family Foundation and the Louis and
Rachel Rudin Foundation, named for Mr. Rudin’s late
parents and grandparents, respectively. The Rudin
Family Foundations exemplify the family’s long
and distinguished tradition of philanthropy in
New York City.
Since 1973, the Rudin Family Foundations have
contributed generously to the support of nearly 900
Rudin Scholars at Einstein. In addition, they have
provided funding for research on Alzheimer’s disease,
cancer, AIDS, glaucoma and reproductive health at
the College of Medicine.
Jack Rudin was instrumental in establishing the
Rudin Scholars Program at Einstein.
Lisa McReynolds, M.D., Ph.D. ’09, a former Rudin
Scholar, met Mr. Rudin at a reception held in his honor
on the Einstein campus in 2006. “He was truly interested in my work and listened carefully as I explained
my thesis research project,” recalls Dr. McReynolds.
30
For Einstein Overseers Kathy and Samuel G. Weinberg
(see facing page), the College of Medicine is a “labor
of love.” Mrs. Weinberg serves as president of the
Einstein National Women’s Division; Mr. Weinberg is a
member of the Board of Overseers’ executive committee and cochairs its facilities and planning committee.
“A great institution is not made up of buildings
alone,” observes Mr. Weinberg. “One only has to visit
Einstein to see that its spirit and uniqueness come
from its exceptional faculty and students. It’s an honor
to support them in their efforts to make the world a
healthier place.”
Service to Einstein is a family tradition. Mrs.
Weinberg’s father, Matthew Kornreich, served on the
Board of Overseers; her mother, Susanne Kornreich,
was a member of the Women’s Division’s National
Board and a vice president of its Westchester/Fairfield
chapter. Lisa Weinberg, Samuel and Kathy’s daughter,
serves as an assistant vice president of the Women’s
Division’s New York chapter; their son, Andrew
Weinberg, is active in the Einstein Men’s Division.
“My parents were passionate about Einstein’s mission to change the world through medical research,”
says Kathy Weinberg. “They were proud to be a part
of the medical school’s illustrious past. Sam and I, and
our children, are proud to be a part of its future.”
The Weinbergs recently made a generous gift in
support of genetic and translational research at the
Michael F. Price Center for Genetic and Translational
Medicine/Harold and Muriel Block Research Pavilion.
With this new commitment, they join a distinguished
group of individuals and foundations designated as
Benefactors of the College of Medicine.
Supporting
Translational
Research at
Einstein
Einstein Overseers Kathy and Samuel G. Weinberg have
made a commitment in support of translational research at
Einstein. In recognition of their generosity, the third-floor
lounge in the Price Center/Block Research Pavilion will be
named in honor of the Weinberg family. The lounge includes
the magnificent spiral staircase that is visible from both inside
and outside the Price Center/Block Research Pavilion. Its
double-helix design represents DNA—the key molecule of
life that is featured on the Einstein logo. This spiral staircase
is an architectural symbol of the new research facility’s
mission of scientific excellence and innovation. 31
BRIDGING THE HEALTH-CARE DIVIDE IN THE BRONX
Bad behaviors cause bad diseases.
Overeating, smoking and alcohol abuse
are among the prime causes of illness and
death nationwide. Einstein researchers have
responded. They are taking simple, safe and
relatively inexpensive interventions to the
streets of the Bronx to improve the health of
its medically underserved population.
Half of all illnesses and deaths in the United States
could be prevented, according to a recent Institute of
Medicine (IOM) study. By stopping smoking, curbing
alcohol consumption, improving their diets, lowering
their stress levels and otherwise changing their behavior, many people could avoid lung cancer, heart disease
and other major killers.
The field of behavioral and social science aims to
motivate people to lead healthier lives. Its practitioners
seek strategies to help them stop smoking, get more
exercise and make other lifestyle changes proven effective in preventing disease. But as the IOM study notes,
less than 5 percent of the two trillion dollars spent
yearly on health care in the United States goes to
reducing behavioral and social risk factors.
The IOM authors would be heartened by visiting
Einstein, where Bronx-based behavioral and social
science research is thriving. A prime example is the
new Marilyn and Stanley M. Katz Comprehensive
Cancer Prevention and Control Program, the result
of a $7 million gift from longtime Einstein Overseers
and Benefactors Marilyn and Stanley M. Katz.
Einstein’s community outreach is not limited to
adults. Through the work of its nationally recognized
Children’s Evaluation and Rehabilitation Center, Einstein
also helps children with developmental disabilities.
The health-care gap between the real and the ideal
is substantial in the Bronx. Einstein researchers are working hard to bridge it.
32
Research at CERC: A New Beginning
Over the last half century, the Children’s Evaluation
and Rehabilitation Center (CERC) has helped thousands of children who have serious developmental
problems. But the need to provide clinical care had
compromised CERC’s ability to conduct research.
Now, for the first time, CERC will have a full-time
research director: neuroscientist John J. Foxe, Ph.D.
Dr. Foxe was recruited from the City University
of New York, where he currently directs the Ph.D.
program in cognitive neuroscience and codirects its
Children’s Research Unit. Many of his projects—and
about 25 members of his Children’s Research Unit
team—will accompany him to Einstein.
“CERC serves about 7,000 children yearly and is an
incredible resource for recruiting patients for clinical
research,” says Dr. Foxe. He expressed gratitude to
Einstein’s National Women’s Division, which recently
completed a three-year, $3 million fundraising initiative to establish CERC’s clinical research program.
Dr. Foxe is planning research partnerships with
other Einstein scientists. For example, he’ll be working with colleagues in genetics and psychiatry to
search for gene mutations or other indicators—called
biomarkers—that may identify children prone to
schizophrenia.
“Schizophrenia is really a neurodevelopmental
disease,” says Dr. Foxe. “If we can identify patients in
Nancy Tarshis, left, director of speech and language
services at the Children’s Evaluation and Rehabilitation
Center, and Debbie Meringolo, associate director of the
infant and toddler team, work with two young CERC
patients. CERC and its positive impact on children in the
Bronx were celebrated recently in a film produced by
Einstein Overseers and longtime Benefactors Philip and
Rita Rosen. To see their film online, visit www.einstein.
yu.edu/cerc.
late childhood who are at risk for schizophrenia, we
may be able to prevent it from developing.”
Much of CERC’s research will involve autism.
This year, Dr. Foxe and his research partner, Sophie
Molholm, Ph.D. (who’ll join Einstein as associate
professor of pediatrics and of neuroscience), were
awarded $2.8 million by the National Institutes of
Health to study why autistic people have trouble processing sounds and other sensory input.
CERC will also assist Michelle Dunn, Ph.D., associate clinical professor of neurology at Einstein and
acting director of the Einstein/Montefiore Autism
Evaluation and Treatment Center, at her intervention
program for autistic children in Co-Op City schools.
“It’s very important for us basic researchers to have
a strong relationship with clinicians such as Dr. Dunn,
who see children with autism every day and understand their problems,” says Dr. Foxe.
33
Snuffing Out Cancer in the Bronx
R a lph a nd J un e Ado r n o
Ralph and June Adorno have made a gift of
a fully paid $500,000 life insurance policy in
support of the new Marilyn and Stanley M.
Katz Comprehensive Cancer Prevention and
Control Program at Einstein.
“We have long admired Marilyn and
Stanley Katz’s commitment to cancer research
at Einstein,” says June Adorno. “After meeting with Dr. I. David Goldman, director of the
Albert Einstein Cancer Center, and some of
the researchers—and seeing for ourselves the
incredible work they’re doing—we decided it
was time to get more involved.”
Supporting the program established by
the Katzes was “a great opportunity to do
something for the good of society that would
help save lives,” adds Ralph Adorno.
A u t i sm Speaks
Autism Speaks has contributed $150,000 as
part of a multiyear commitment to support a
research study led by Thomas V. McDonald,
M.D., professor in the departments of
medicine and of molecular pharmacology,
using the Drosophila (fruit fly) model to
identify possible drug treatments for
autism spectrum disorders.
34
Smoking is the leading cause of preventable death and
disease in the United States and the Bronx. Bruce D.
Rapkin, Ph.D., director of Einstein’s new Marilyn and
Stanley M. Katz Comprehensive Cancer Prevention and
Control Program, wants to snuff out smoking all over the
Bronx, but especially among those most endangered by
the habit.
“About 18 percent of Bronx adults are smokers,”
says Dr. Rapkin. “All too often, those most resistant to
quitting are people whose health is already precarious—
particularly individuals with substance abuse or mentalhealth problems or who are HIV-positive. They haven’t
benefited from conventional antismoking campaigns,
so we’ve created a Tobacco Prevention and Cessation
Think Tank to understand the nature of their addiction.”
Think-tank members come from half a dozen
Einstein departments, including family and social
medicine and psychiatry. They meet monthly to devise
smoking-cessation programs geared toward recalcitrant
smokers. They are also applying for grants to help them
reach this population. “Our mission at Einstein extends
from community prevention and early detection all the
way to support for cancer patients, survivors and their
families,” Dr. Rapkin says of his ambitious agenda.
Dr. Rapkin was recruited to Einstein from Memorial
Sloan-Kettering Cancer Center, where he worked for 16
years—the last six as director of the Community Health
and Health Disparities Laboratory.
Some of the innovative projects that Dr. Rapkin
started at Memorial Sloan-Kettering have become part
of his new Einstein program. Queens Library HealthLink
is an especially notable success story.
“The philosophy behind Queens Library HealthLink
is to let each community find its own best path to overcome health disparities,” he says. Key to this project’s
achievements are its Cancer Action councils—groups of
dedicated volunteers who meet monthly at 14 Queens
libraries to discuss expanding access to cancer screening and treatment services in their communities.
In Flushing, a neighborhood with many immigrants
who speak little or no English, the local Cancer Action
Council drew up cancer-resource guides and other outreach materials in Spanish, Chinese and Korean.
“I speak five languages and joined this group
because I want to use my language skills to help save
lives,” says volunteer Mabel Narbutt. She visits restaurants and beauty parlors in Flushing, talking to people
in Mandarin and Taiwanese about the group’s events
and distributing its resource guides.
Bruce D. Rapkin, Ph.D.
“Most of these people don’t have health insurance
and appreciate learning things such as where they can
get free mammograms,” she adds.
The Cancer Action councils identify community
needs and plan programs with help from Dr. Rapkin’s
team at Einstein. These programs, which also include
smoking-cessation workshops and cancer support
groups, have so far reached more than 4,000 Queens
residents. And participating in this sort of grassroots
effort also benefits Dr. Rapkin and his colleagues.
“There are lots of things we learn by working with
partners in the community—even setting the research
agenda together—that you don’t get to learn in a
carefully controlled lab or clinic setting,” says Dr.
Rapkin. “You get new insights into the barriers and
motivations that affect people.”
Plans call for establishing Cancer Action councils in
the Bronx over the coming months, adapting the successful Queens program to the patient population of
the local community.
In developing Bronx-based programs, the new
Einstein cancer prevention team takes a special interest in the psychological toll that cancer takes. For that
reason, Dr. Rapkin is working with Alyson Moadel,
Ph.D., associate professor of medicine and of epidemiology & population health at Einstein, to create a new
Psycho-Oncology Translational Research Clinic.
Dr. Moadel and her colleagues will develop and
study psychological and behavioral interventions for
cancer patients and their families—addressing, for
example, sexual-health issues in couples after cancer
surgery or helping head and neck cancer patients
quit smoking.
“There are lots of things we learn by working with partners in the community that
you don’t learn in a lab or clinic setting.”
“We want to determine the kinds of programs
that would be most useful and adapt them to people
in the Bronx,” says Dr. Rapkin. “I’m excited about
this because there hasn’t been enough research on
psychological or behavioral care for cancer patients of
color or who speak Spanish or have limited resources.”
Dr. Rapkin and his team will continue forming new
partnerships with community-based organizations and
to seek their input as they roll out more programs.
They are now talking with Bronx agencies serving lowincome populations about creating a breast cancer
screening program aimed at reaching women who are
not getting mammograms on a regular basis.
“You need these community partnerships to reach
the people who might otherwise fall through the
cracks,” says Dr. Rapkin.
35
New Treatment for Heroin Addicts
Above, Chinazo Cunningham, M.D., M.S. (top) and
Lynne M. Holden, M.D.; at right, Chinedu Nabuobi, a
second-year Einstein medical student in the Mentoring
in Medicine program meeting with students interested
in health-care careers.
T h e R o bert W o o d J o h ns o n
F o u nd at i o n
The Robert Wood Johnson Foundation has
committed $409,543 to support the research
of Einstein scientists, including a multiyear
grant of $299,999 for a study led by Alain
Harris Litwin, M.D., M.S., M.P.H., associate
professor of clinical medicine and of clinical
psychiatry and behavioral sciences. The study
involves treating people in methadone clinics
who have hepatitis C.
36
Boosting Minority Students into
Health-Care Careers
Lynne M. Holden, M.D., is cofounder of Mentoring in
Medicine (MIM), an Einstein/Montefiore partnership that
introduces minority students to careers in health care.
“We wanted to help kids who have a dream but don’t
have role models they can emulate,” says Dr. Holden,
associate professor of clinical emergency medicine
at Einstein.
Since helping form MIM in 2006, Dr. Holden and her
team have recruited 500 volunteer mentors—physicians,
paramedics and others—who talk to students about the
rewards of health-care careers and help them apply to
schools that train health professionals.
Nearly 6,500 students have participated in MIM programs, including after-school clubs and an internship in
which they volunteer in Montefiore’s emergency department. Eighteen MIM participants are now studying to be
physicians, physician assistants, nurses, pharmacists or
public-health professionals.
In October, Dr. Holden was named a Robert Wood
Johnson Foundation Community Health Leader for her
work with MIM.
“The entire Einstein community is tremendously proud
of Dr. Holden,” says Edward R. Burns, M.D., Einstein’s
executive dean. “Her work with MIM is an innovative way
to increase the diversity of the country’s health-care workforce and, ultimately, reduce health disparities.”
In 2002, an alternative to methadone called buprenorphine received approval for treating opiate addiction.
Chinazo Opia Cunningham, M.D., M.S., associate
professor of medicine at Einstein, is now conducting
an innovative program in the South Bronx that uses
buprenorphine to help people stop using heroin. She
was motivated by the tremendous growth in opiate
abuse in the area, the limited options for drug treatment
and the benefits that buprenorphine provides.
Compared with methadone, buprenorphine has a
better safety profile, as it is less likely to be misused or
diverted and less likely to result in an overdose. As a
result, the treatment is approved for use in primary-care
settings, such as Dr. Cunningham’s Bronx facility. And
it is convenient as well: After a couple of initial office
visits, patients return only every four to eight weeks to
get their supply of buprenorphine tablets.
“This program has helped hundreds of drug users
in the Bronx,” says Dr. Cunningham. “Our patients are
saying things like, ‘You really saved my life’ and ‘I never
thought I would be clean this long.’”
To expand buprenorphine’s use within the
Montefiore/Einstein system, Dr. Cunningham offers
seminars to physicians and to residents who care for
hospitalized patients. She wants them to refer patients
to her program and receive the necessary training to
prescribe buprenorphine themselves.
Jeffrey E. Pessin, Ph.D., the Judy R. and Alfred A.
Rosenberg Endowed Professorial Chair in Diabetes
Research, at work in his lab. Dr. Pessin is a professor
in the departments of medicine and of molecular
pharmacology at Einstein and directs its Diabetes
Research Center.
Judy R. Rosenberg’s Lasting Legacy
of Support for Diabetes Research
Diabetes is another health problem that is especially
prevalent in the Bronx. With the help of its donors,
Einstein has launched programs to combat this worsening epidemic.
Judy R. Rosenberg was one of a pioneering group of
women who, beginning in 1953, helped turn the dream
of a medical school at Yeshiva University into reality. A
passionate supporter of the College of Medicine until
her death in 2008, Judy served on the Einstein Board of
Overseers for 30 years and was a founder of Einstein’s
National Women’s Division.
Judy and her husband, Alfred, were Benefactors of
the College of Medicine, and they endowed the position of Faculty Scholar in Diabetes Research at Einstein.
In 1996, following Alfred’s death, Judy established the
Judy R. and Alfred A. Rosenberg Endowed Professorial
Chair in Diabetes Research. The Rosenberg Chair is
currently held by Jeffrey E. Pessin, Ph.D., director of
Einstein’s Diabetes Research Center.
The Jon as E hr l ich
Char i tab l e Tru s t
The Jonas Ehrlich Charitable Trust has
pledged $160,000 to support a collaborative
research project to identify the underlying
causes of autism and other developmental
disorders. The study is being conducted by
basic scientists at the Price Center/Block
Research Pavilion together with clinical
experts at Einstein’s Children’s Evaluation
and Rehabilitation Center.
37
Bridging the Student to MD Divide
For the first time in its 50-year history,
Einstein now has a dedicated center on
campus where—before they actually see
patients—medical students can master the
skills they’ll need to become competent
and compassionate physicians.
Philanthropy plays a vital role in improving medical
education at Einstein, as the recently opened Ruth L.
Gottesman Clinical Skills Facility illustrates.
The new facility is named for the current chair of
the Einstein Board of Overseers, who also served on
the Einstein faculty for more than three decades. Its
$3 million cost was covered by part of a $25 million gift
from Ruth and her husband, David Gottesman, that also
supports stem cell and epigenomic research at Einstein.
The College of Medicine is indeed fortunate that a
number of donors in addition to the Gottesmans have
generously supported the teaching side of its mission
over the past year. Their gifts have met a wide range
of educational needs, from renovating laboratories to
funding scholarships.
The Clinical Skills Facility was created by renovating
a 23,000-square-foot space in the eight-story Van
Etten building—a step toward fulfilling the College
of Medicine’s Campus Master Plan, in which Van
Etten plays a key role (see page 41). And the facility
immediately enhances the quality of medical education
at Einstein.
38
the gottesman clinical skills facility
Until the Ruth L. Gottesman Clinical Skills Facility
opened in September, Einstein lacked a location on
campus dedicated to teaching students the skills
essential for becoming well-rounded, compassionate
physicians. Instead, Einstein students had to travel to
other medical schools to be evaluated and get feedback on their mastery of those important skills.
At the heart of the Einstein facility are 23 rooms
that can simulate physicians’ examining or hospital
rooms. They can also function as classrooms and are
equipped with examining tables and standard medical
instruments for checking the eyes, ears, throat and
nose and taking blood pressure.
First- and second-year medical students take part
in the Introduction to Clinical Medicine Program. Here
they learn basic clinical skills and knowledge needed
for their initial encounters with real patients. For firstyear students, the rooms of the Clinical Skills Facility
function as small classrooms for mastering communication skills—how to develop rapport for a good doctorpatient relationship and how to interview patients
or actors trained to portray “standardized patients”
(people with a certain set of symptoms). Second-year
students use the rooms primarily as places for practicing physical examination skills on one another.
During their third year, students come to the
center to participate in the Clinical Skills Assessment
Einstein’s new Clinical Skills Facility was made possible
by the generosity of Ruth L. Gottesman, Ed.D., left, chair
of the Einstein Board of Overseers. She and Felise Beth
Milan, M.D. ’88, director of the Clinical Skills Assessment
Program, are shown in one of the facility’s fully equipped
practice rooms.
Program. In this program the standardized patients
assess students’ skills during eight patient encounters. “The program aims to ensure that our students
have adequate clinical skills and to give them feedback on their strengths and weaknesses,” says Felise
Beth Milan, M.D. ’88, director of the Clinical Skills
Assessment Program as well as the Introduction to
Clinical Medicine course at Einstein. The program
also preps them for the Clinical Skills Board Exam
(Step 2 CS), which students must pass to graduate
from Einstein and receive their medical licenses.
“A big improvement in teaching these skills is in
having the actual equipment,” says Mimi McEvoy,
M.A., C.P.N.P., a codirector of the second-year
Introduction to Clinical Medicine course at Einstein.
Previously, she notes, students practicing their physical-exam skills made do with makeshift exam tables
consisting of mats thrown over classroom tables in the
Belfer building. The standard medical-office exam
tables offered in the Clinical Skills Facility are especially useful because the student can practice making
the patient more comfortable by pulling out the
39
“Interacting with your first patient
is an experience you never forget.
Being in a realistic learning
environment before that, with
all the cues, removes some of
“If you’re a second-year student
learning to do physical exam
skills in a more real situation,
the leap to the clinical is going
to be much smaller.”
the anxiety.”
– J essica Schre i ber -Zin aman
Class o f 2010
Teaching Assistant in Clinical Skills
– Jonath an Peled, C l ass of 2 0 1 0
Medical Scientist Training Program
extension for the patient’s legs. Later, when students
are tested in a simulated medical-office setting during
the third-year assessment program and licensing
board examinations, they will be familiar with this
simple technique.
Each of the facility’s 23 rooms has a wall of one-way
mirrored glass so faculty can observe the students in
action. Ten rooms are equipped with state-of-the-art
“The ability to easily do video recording
of students as they hone their clinical
skills is huge. You can spot mistakes,
and you can review the video with
the learners.”
video cameras on tracks in the ceiling, to help professors observe students as they interact with fellow
students and actual or standardized patients.
“The ability to easily do video recording of students
as they hone their clinical skills is huge,” says Dr. Milan.
“You can spot mistakes, and you can review the video
with the learners, pointing out how they could improve
their interactions with patients.”
40
Building a Better Training Center
While the clinical training facility was in the planning
stages, Dr. Milan toured similar facilities along with
project manager Chris Cimino, Senior Facilities
Director Sal Ciampo and their architects. “We went
to the new facilities at Thomas Jefferson and Drexel
in Philadelphia, to the University of Medicine and
Dentistry of New Jersey’s center in Newark, and to
Weill Cornell in Manhattan,” Dr. Milan says. “We took
lots of notes about what we liked and what we didn’t
like.” The result? The new Einstein Clinical Skills Facility
is one of the largest and best equipped in the country.
“Our primary goal was to make sure we had
enough rooms,” says Dr. Milan. “We also wanted these
rooms to be flexible, equipped with easily reconfigured
furniture so we can quickly transform them from teaching physical diagnosis, for example, into assessment
rooms housing the latest in audiovisual equipment.”
Technology will also figure prominently in the
1,800-square-foot Simulation Center, soon to be built
in the facility’s Wing B. The center will house surprisingly realistic mannequins and computerized devices
for teaching and testing essential clinical skills such as
intubation, resuscitation and pelvic exams.
Dr. Milan hopes to broaden the scope of the
Clinical Skills Facility to include even more educational
programs for enhancing medical skills—not just for
medical students but for residents and practicing
physicians as well. “With techniques for diagnosis and
therapy improving all the time,” says Dr. Milan, “this
facility can help specialists keep up with the constantly
changing medical landscape.”
The Van Etten building, which houses the Clinical
Skills Facility, will assume an even bigger role as the
Einstein campus evolves in the coming years.
Welcome to Einstein’s Future
The 2007 strategic research plan laid out an ambitious
future for Einstein: “a state-of-the-art research environment that will foster scientific investigation at all levels
from the bench to the bedside and from the clinic to
the community.”
The visionary yet pragmatic road map for realizing
that goal is Einstein’s Campus Master Plan. Rather than
emphasizing new construction, the plan offers strategies for optimizing what is now available: reconfiguring
and connecting buildings via walkways; consolidating
certain departments and relocating others; and opening
up interior spaces and corridors to the outdoors. The
result will be a more efficient, convenient and pleasant
environment that draws people onto the campus.
“The beauty of the Master Plan is its flexibility,”
says Allen M. Spiegel, M.D., the Marilyn and Stanley
M. Katz Dean. “It offers the College of Medicine room
to grow through changes that can be implemented
on an incremental, as-needed basis depending on
At left, Einstein students hone their clinical skills under the
supervision of Martin N. Cohen, M.D. Above: the Van Etten
building as envisioned in the Campus Master Plan.
available funding. All these changes promote the
major objective of our strategic research plan—to
create a collaborative, state-of-the-art environment that
will attract and retain the best and brightest students
and scientists.”
The Master Plan’s first priority is to make the most
effective use of existing facilities—and fully occupying the Van Etten building is crucial to that effort.
Constructed as a 500-bed tuberculosis sanatorium in
the early 1950s, the eight-floor, 360,000-square-foot
Van Etten building was recently leased to Einstein by
Jacobi Hospital.
This fall’s opening of the new Ruth L. Gottesman
Clinical Skills Facility on the second floor marks
Einstein’s official arrival in Van Etten. The Master Plan
envisions relocating other existing clinical education
programs as well as clinical facilities to Van Etten,
including the Children’s Evaluation and Rehabilitation
Center, Aging Studies and the Anatomy Labs. In
addition, to accommodate a desired increase in
on-campus housing, selected wings of Van Etten will
be converted to some 200 studio apartments for
medical and doctoral students.
41
Gift Agreement Initiated by
Richard Netter Supports Medical
Education at Einstein
Scholarships hold the key
Private philanthropy plays a vital role in supporting
Einstein’s outstanding research programs. In addition, our donors provide funding for scholarships
that are crucially important for Einstein medical
students. Scholarships allow many students to pursue their dream of a career in biomedical research
or clinical practice. Through scholarship support,
donors are investing in talented Einstein students
and in the future of American health care.
So l a nd D o r o t hy S m o l e n
E nd o wed S c ho l ars hip F un d
The College of Medicine has received a
$150,000 contribution from the Sol and
Dorothy Smolen Endowed Scholarship Fund.
The late Sol and Dorothy Smolen, who passed
away in 2004 and 2005, respectively, were
longtime supporters of many Jewish and
other charitable organizations. The couple
established visionary endowments under their
wills, including the Sol and Dorothy Smolen
Endowed Scholarship Fund, which will provide
vital scholarships over the course of 30 years
to deserving students at Einstein.
42
Gerald H. Levine Scholar
Rachel E. Louie, Class of 2010
Rachel Louie, above, always dreamed of becoming a
pediatrician. After earning her bachelor’s and master’s
degrees in biology from the University of California, San
Diego, she applied to 15 medical schools. She chose
Einstein because of “the impressive opportunities it
offers for students interested in primary care.”
Her avid interest in health-care delivery, both in
the United States and abroad, led Rachel to Einstein’s
Global Health Fellowship Program. During the summer
following her first year of medical school, she spent four
weeks in Guatemala, living with a host family, attending
Spanish classes and volunteering at a local clinic.
Rachel hopes these experiences “will help me
evolve into a more open-minded physician and develop
stronger relationships with my patients while helping me
address problems of access to care in my own country.”
The issue of health-care access, particularly for the
very young, is Rachel’s passion. “If all children were followed regularly by a pediatrician,” she says, “they’d be
more likely to receive early interventions that could prevent complications from health issues such as obesity.”
In 2009, Rachel received a scholarship from the
Gerald H. Levine Endowed Scholarship Fund. “This generous award not only contributes to my medical education,” she says, “but it will contribute to my career, my
future and my dreams.”
A commitment of $500,000 will support and endow
an Einstein assistant deanship at Beth Israel Medical
Center, Manhattan Campus, one of Einstein’s five affiliate teaching hospitals. The joint gift consists of two
separate contributions of $250,000 from the Robert
Blauner Testamentary Trust and the Herbert and Nell
Singer Foundation. It was arranged by the late Richard
Netter, Esq., who was a longtime board member of
Beth Israel and an established donor to Einstein.
The assistant dean oversees the clinical training of
Einstein students during their third- and fourth-year
clinical rotations at the hospital. The two gifts fostered
by Mr. Netter exemplify the strong working relationship
between Einstein and Beth Israel.
“These commitments reflect Mr. Netter’s keen
understanding of how Einstein and Beth Israel collaborate to produce outstanding doctors,” notes Stephen
Baum, M.D., senior associate dean for students, who
was instrumental in obtaining the pledges.
This is Mr. Netter’s second gift to Einstein. The
“Thanks to Scandinavia” educational scholarship fund,
cofounded by Mr. Netter in gratitude for the heroic
efforts of Scandinavian people to save Jews during
World War II, has provided support since 1993 for postdoctoral fellows at Einstein who come from Denmark,
Finland, Norway and Sweden.
Lawrence Schleifer:
Helping Students in Need
“I’m Jewish,” says Lawrence Schleifer, “and my
responsibility is to help people.” Mr. Schleifer
and his late wife, Friedericka Steinbach Schleifer,
M.D., decided to leave their joint estates to
Einstein to support scholarships for needy medical students. Recently, Mr. Schleifer, who is 95,
decided to make an “advance” on their legacy
by giving $100,000 to Einstein and $1 million to
an Einstein charitable remainder trust.
“Albert Einstein College of Medicine is a
very special place for me and especially for
Friedericka,” he says. Friedericka Steinbach
Schleifer graduated from medical school in
Vienna in 1937—a year before the Nazis invaded.
She did her residency in Nazi-occupied Austria,
desperately seeking visas so that she and her
parents could flee to the United States. By sheer
luck she was able to obtain a visa, but only for
herself. Friedericka wasn’t allowed to take any
money with her and arrived in New York with only
her furniture and her microscope. After the war,
she discovered that her parents had perished in
an extermination camp.
The Schleifers were married for 39 years.
Lawrence Schleifer began his career as a pharmacist, then worked for a pharmaceutical company.
A scholar by nature, he later earned a master’s
degree in history and taught high school and college students. Today, Lawrence Schleifer shares
his vast knowledge of Jewish and comparative
culture with students in adult-education classes.
43
Bridging the Global Health-Care Divide
Einstein’s mission is improving human health—
locally, nationally and globally. Each year,
Einstein faculty members and some 30 medical
students travel to underdeveloped countries,
where they provide badly needed medical
care and gain valuable knowledge for
combating disease.
The Global Health Center is the clearinghouse for
Einstein’s medical outreach to the world—and the
international activity at the College of Medicine has
never been more intense. “Thanks to Al Kuperman, our
outgoing dean of education, Einstein is way ahead of
the curve in terms of global health activities,” says Paul
R. Marantz, M.D., M.P.H., associate dean for clinical research education. He points to Dr. Kuperman’s pioneering 1976 proposal to encourage medical students to
gain experience in developing countries.
The Global Health Center was created in 2007 to
bring all international education and research programs
under one roof and coordinate student and faculty
participation. “No matter where people go or what their
projects are, they’ll confront the same basic problems,”
says Dr. Marantz. “They’ll have to deal with the red
tape involved in transporting samples and know what
types of visas to get. So why reinvent the wheel each
time someone goes overseas? A single center allows
people to use existing channels to get answers more
efficiently.”
The Global Health Center boasts 28 initiatives
worldwide, including clinical and research programs
in Argentina, Bangladesh, Brazil, Ethiopia, Guatemala,
India, Nigeria, Rwanda, South Africa, Uganda and
Vietnam. The center allows Einstein to maintain its
prominent role in providing outstanding medical care to
the developing world.
44
Combining Concern and Compassion
By the time she was nine, she knew she wanted to be
a doctor. By age 12 she had chosen diabetes as her
specialty, after reading about Frederick Banting and
Charles Best, her fellow Canadians, who discovered
insulin in 1921. Then came dreams of becoming a
medical missionary—which posed a problem.
“I wanted to be a humanitarian and help the poor
and vulnerable, but my passion—diabetes—was a
First World problem in those days,” recalls Meredith
A. Hawkins, M.D., professor of medicine and director
of the Global Diabetes Initiative at Einstein.
That conflict resolved itself 13 years ago, when Dr.
Hawkins volunteered her services in Romania in lieu
of a vacation. There she discovered the sad truth that
diabetes was surging in the developing world as well.
“Because they’ve gained access to cheap but poorquality food, a lot of people can now for the first time
actually afford to become obese, and obesity is the
leading cause of type 2 diabetes,” says Dr. Hawkins.
Obesity-related diabetes accounts for the majority
of cases in underdeveloped countries. But increasingly, says Dr. Hawkins, people are being diagnosed
with diabetes caused not by too much food but by
too little—a disease known as malnutrition diabetes.
This poorly understood form of diabetes may afflict
millions of people worldwide but is only now being
recognized as a major health problem.
Einstein’s Elizabeth Walker, Ph.D., and Meredith Hawkins,
M.D. (second and third from left, respectively), visit a
diabetes patient (left) at her home in Kampala, Uganda,
last August. They had helped to organize a symposium
on managing diabetes for doctors and nurses from 22
Ugandan health clinics.
“Malnutrition diabetes affects poor people living
on a dollar a day in rural areas of Africa and Asia,”
says Dr. Hawkins. “The disease mainly strikes adolescents and young adults. If nothing is done for them,
they usually die within six months to a year of being
diagnosed. We suspect that stressful events may help
trigger the disease.” She notes that stress may have
played a role in the case of Isaac, a Ugandan teenager
orphaned at a young age (see sidebar on page 47).
Malnutrition diabetes has probably existed for
a long time. But until recently it has been eclipsed
by the infectious diseases—particularly measles,
tuberculosis and HIV/AIDS—that shorten so many
lives in Uganda and other impoverished countries.
Unfortunately, doctors in affected areas typically don’t
know that malnutrition diabetes exists.
“The doctors in these countries read medical
journals that come from the West, so they don’t learn
about malnutrition diabetes and don’t suspect it in
their patients,” says Dr. Hawkins.
To increase awareness, Dr. Hawkins directs a
clinical education project in Uganda as part of the
45
Being a compassionate physician, Dr. Hawkins points
out, is in some ways a luxury. “For those of us who’ve
slept well and are well fed, who work in supportive environments and are adequately compensated, treating
patients with kindness comes a lot easier.”
Life Lessons
Above, two scenes from the diabetes clinic in Kampala,
Uganda. At right, Hanna Lee, M.D., ’09, with her research
advisor, Dr. Hawkins.
Einstein Global Diabetes Initiative. Last August
Dr. Hawkins headed a team that organized a symposium on diabetes management for 100 doctors and
nurses from 22 Ugandan health clinics. Topics included
nutrition, drugs, foot and wound care, and handling
emergencies.
The Einstein Global Diabetes Initiative is also at
work in India to advance current knowledge about
malnutrition diabetes. There, Dr. Hawkins and other
Einstein researchers partner with the Christian Medical
College of Vellore—the so-called Mayo Clinic of India.
This medical school and 3,000-bed hospital are located
in the southeastern part of the country, where the
poverty rivals that of Africa. The upcoming clinical
studies at Vellore will be the first to address the
urgent questions surrounding this disease.
“Based on current knowledge, we don’t know
whether or not malnutrition diabetes is mainly a problem of lack of insulin, like type 1 diabetes. Therefore,
it’s often treated the same way—with insulin injections,” says Dr. Hawkins. “But insulin treatment is very
challenging in these settings, and we really don’t know
whether it’s necessary. So we urgently need to learn
whether malnutrition diabetes should be treated
differently and, if so, what treatments will help.”
46
The Indian studies will also look at how nutrition can
influence the disease. “Some people with malnutrition
diabetes may well have passed the point where they
can improve with better nutrition,” says Dr. Hawkins.
“But for other patients, switching to a nutritious diet
does seem to help. And we may be able to prevent
the disease with certain vitamins or amino acid supplements. There are a lot of knowledge gaps left to fill.”
“Part of it is to teach medical skills, but part
of it, honestly, is to model compassion in a
setting where it doesn’t come as easily.”
Though geared toward education and research, Dr.
Hawkins’ global outreach includes the kind of face-toface contact with patients that she dreamed of as a girl.
“When we’re in Uganda, I give lectures but also try to
do bedside teaching,” she says. “Part of it is to teach
medical skills, but part of it, honestly, is to model compassion in a setting where it doesn’t come as easily.”
Uganda’s overburdened health-care system, she
explains, can demoralize young doctors. She tells of a
young intern who, while running himself ragged caring
for 35 very ill patients, brushed aside her offers to get
painkillers for a patient. “Don’t worry,” he told her. “If
you’re here long enough, you’ll stop caring too.”
Hanna Lee, M.D., Class of 2009, thought she was reasonably worldly. Raised in South Korea and educated
in the United States, she had traveled in the Philippines
and taught school in the South Bronx. But what really
opened her eyes was a three-week trip to India in 2008,
sponsored by her research advisor, Dr. Hawkins. In
particular, this traveler was struck by how India’s health
professionals managed to do more with less.
“We saw a patient with breathing problems during
a visit to a local hospital,” Dr. Lee recalls. “Without so
much as an X-ray, doctors were able to differentiate
pleural effusion from fibrotic lung disease—just by feeling the spaces between her ribs and by watching her
chest rise and fall. I definitely learned some new clinical
skills there.”
She also spent time in a rural “health camp”—a
makeshift clinic that dispatches clinicians to a different
village daily, delivering everything from dental care to
diabetes counseling.
“Everything was so different in India—the culture,
the food, the language. It made me realize how health
care has to be tailored to the individual. What works for
one patient might not work for another,” says Dr. Lee.
She is now a resident in medicine at Montefiore Medical
Center in the Bronx, one of the nation’s most diverse
communities. The knowledge gained from those three
short weeks abroad will serve her well there.
The MAC AID S Fund
The MAC AIDS Fund (formerly the MAC
Global Foundation) has awarded a $231,839
grant to the School-based Teenage Education
Program (STEP). Founded and directed by
Rosy Chhabra, Psy.D., assistant professor of
pediatrics at Einstein and a native of India,
STEP trains Indian college students to raise
awareness among Indian adolescents about
the dangers of HIV and alcohol abuse.
The Face of Malnutrition Diabetes
At first glance, Isaac looks like any other 15-yearold Ugandan boy, all knees and elbows. But he is
anything but normal. Isaac has malnutrition diabetes, a newly recognized and little-studied form of
the disease that occurs almost exclusively in the
developing world.
Sadly, Isaac’s misfortunes don’t end there.
Orphaned years ago, he lives on the street and
occasionally with his grandmother (who has serious problems of her own) and cannot afford to
attend school. He receives outpatient care at
Mulago Hospital in Kampala, but is forced to sell
the insulin he receives there to buy food. And he
may have tuberculosis.
“Unless we can get proper care and nutrition
for Isaac, he probably won’t survive another year,”
says Dr. Hawkins, who has been championing the
boy’s cause since meeting him at Mulago Hospital
last August. Taking the longer view, Dr. Hawkins
says that “we need to get children with malnutrition diabetes into the health-care system, identify
the nutrient deficits that cause the disease, figure
out how to treat it and show that we can improve
outcomes for these kids.”
It’s a tall order, but Dr. Hawkins is trying to
fill it—one child at a time, if necessary.
Readers wishing to learn more about the
Einstein Global Diabetes Initiative can write
to the Einstein Global Diabetes Initiative, 1300
Morris Park Avenue, Belfer 709, Bronx, NY 10461,
or email [email protected]
47
New Advances against an Old Disease
Unraveling TB’s Cloak of Invisibility
J. K. Rowling may have popularized the idea of
an invisibility cloak in her Harry Potter novels,
but she certainly didn’t invent it. Mycobacterium
tuberculosis, the microbe that causes TB, came
up with this trick eons ago. It becomes invisible
to the human immune system by hiding inside
and disabling macrophages, the body’s first-line
defense against infectious microorganisms.
“Normally, when a macrophage is invaded by
bacteria or viruses, the macrophage undergoes
something called programmed cell death, or
apoptosis,” says Michelle Maxson, a fifth-year
doctoral candidate in Dr. William Jacobs’ lab. In
essence, the macrophage commits suicide, taking the invading microbe along with it. But TB
bacteria—particularly the more virulent strains—
can block this process and continue residing
(and multiplying) within macrophages. How do
they do it?
Over the last several years, Michelle has
identified a set of mycobacterial genes that seem
to be implicated in turning off a macrophage’s
self-destruct mechanism.
“Now I’m doing the genetics to remove these
genes from the TB bacterium to see if we can
create strains that promote apoptosis in macrophages,” says the young researcher. “If so,
we might be able to use this knowledge to
design a TB vaccine that elicits a stronger
immune response.”
As Rowling fans know, Harry’s invisibility cloak
is not invincible. Thanks to Michelle, M. tuberculosis’s cloak may not be, either.
48
Tuberculosis (TB) is responsible for two million deaths
each year, primarily in Africa and Asia. But it also strikes
close to home. In 2007, an Atlanta man suspected of
having a drug-resistant form of TB caused an international sensation when he ignored warnings from health
officials to stay put and instead boarded a flight to
Europe. He was placed under federal quarantine when
he returned.
Multidrug-resistant TB and its deadlier cousin,
extensively drug-resistant TB (XDR-TB), are on the rise,
particularly in the developing world, with half a million
new cases a year. Fortunately, Einstein investigators
have reported two significant advances in the past year
that could help keep drug-resistant TB in check.
Clinicians need a rapid, inexpensive and simple test
for detecting whether someone is infected with TB, so
the patient can be isolated and quickly begin treatment.
In March, researchers from Einstein and the University of
Pittsburgh announced a new method that diagnoses TB
infection rapidly and also specifies whether the infecting
bacteria are sensitive or resistant to antibiotics.
“We’re optimistic that we can shorten the
diagnostic time in places like rural Africa
from weeks to days or even hours.”
The ingenious technique employs viruses called
bacteriophages that infect TB bacteria. The viruses are
engineered to carry the gene for luciferase—the protein
that makes fireflies glow. When viruses with their fireflygene cargo are added to a patient’s sputum sample,
they infect only TB bacteria. Infected bacteria “express”
the firefly protein, making them glow bright green
under a standard microscope—a clear indication that
the sample contains TB bacteria.
By adding antibiotics, physicians can detect whether
the TB bacteria are sensitive or resistant to specific
antibiotics. If the TB strain is sensitive to streptomycin,
for example, the bacteria will succumb to the antibiotic
and won’t glow. But a streptomycin-resistant strain will
survive, become infected by the virus and announce its
resistance by glowing.
“This detection technique allow us to bypass the
existing method of diagnosing TB, which requires cultivating notoriously slow-growing TB bacteria in a biosafety level 3 containment area—a time-consuming and
costly process,” says study coauthor William R. Jacobs,
Jr., Ph.D., professor of microbiology & immunology and
William R. Jacobs, Jr., Ph.D., and John S. Blanchard, Ph.D.
of genetics at Einstein. “We’re optimistic that we can
shorten the diagnostic time in places like rural Africa
from several weeks to several days or even hours, so
that effective treatments could begin much sooner.”
The research by the Einstein/Pittsburgh group was
funded by a major new initiative from the Howard
Hughes Medical Institute (HHMI). The institute is partnering with the University of KwaZulu-Natal in South
Africa to establish an international research center
focused on the TB and HIV coepidemics. Dr. Jacobs,
an HHMI investigator at Einstein, will direct the institute’s research on rapid and effective TB tests.
South Africa has more people infected with HIV
than any other country. Its KwaZulu-Natal province is
especially hard-hit, with as many as 40 percent of the
population infected by HIV. Tuberculosis was a major
public-health crisis in South Africa even before the HIV/
AIDS epidemic; coinfection with both HIV and TB is
particularly lethal because immune systems weakened
by HIV can’t defend against TB infection.
In results published in Science magazine, a separate
team of Einstein investigators recently reported that
a combination of two drugs—both already approved
by the U.S. Food and Drug Administration for fighting other bacterial infections—shows promise for
treating XDR-TB. The drugs work in tandem: one of
them (clavulanate) inhibits a bacterial enzyme that
normally shields TB bacteria from the other antibiotic
(meropenem, a member of the beta-lactam class of
antibiotics that also includes penicillin).
Current TB therapy requires four antibiotics that
must be taken for at least six months. “If this antibiotic
combination is proven in human subjects, simplifying
treatment to just two drugs that work against drugsusceptible, multidrug-resistant and XDR-TB could
help patients better adhere to therapy,” says John
S. Blanchard, Ph.D., the Dan Danciger Professor of
Biochemistry and the paper’s senior author.
”This drug combination has tremendous
potential for treating not only extremely
drug-resistant cases, but also routine
TB cases.”
A phase-two clinical trial of the two-drug combination is planned for South Korea. Additionally, as part
of a collaboration between Montefiore Medical Center
and the Nelson R. Mandela School of Medicine, a
separate trial will test the drug combination’s potency.
“We feel that this drug combination has tremendous potential for treating not only extremely drugresistant cases, but also routine TB cases,” adds Brian
Currie, M.D., M.P.H., professor of medicine and of
clinical epidemiology & population health.
49
Samples for Survival
Marla J. Keller, M.D.
E arle B. W e iss, M .D . ’6 1
Earle B. Weiss, M.D. ’61, has made a planned
gift of $900,000 to support global health
programs at Einstein. Now retired from a long
and distinguished career in pulmonary medicine, Dr. Weiss developed a strong interest in
global health while serving as a visiting professor at Mexico’s University of Guadalajara
Medical School in 1973, 1977 and 1982. There
he taught respiratory medicine and frequently
visited rural health clinics. His experiences
convinced him that modern medicine should
be directed toward helping the world’s developing nations.
“As an Einstein alumnus, I’m proud that
Einstein has been at the forefront of introducing global health experiences into the
medical school curriculum,” says Dr. Weiss.
“Practicing medicine in a developing country
benefits both the students and the communities served. It’s very gratifying to have the
opportunity to contribute to the growth of
this wonderful and important program.”
50
Without setting foot in Africa, Marla J. Keller, M.D., an
associate professor of medicine and of obstetrics &
gynecology and women’s health, is studying 80 Rwandan
women. She is analyzing fluid samples from their genital
tracts to better understand immune responses that may
help prevent sexually transmitted diseases.
Dr. Keller’s work is sponsored by a $25,000 pilot
grant from Einstein’s Global Health Center, one of three
such grants awarded last year. She gets the Rwandan
samples from her Einstein colleague Kathryn Anastos,
M.D., professor of medicine and of epidemiology &
population health. Dr. Anastos runs the only cervical
cancer screening and prevention program in Rwanda.
Dr. Keller is working to develop better vaginal
microbicides. Contained in creams, gels or rings that
women self-administer, microbicides inhibit HIV or other
disease-causing sexually transmitted microbes so they
don’t get passed from one person to another. Since
arriving on campus in 2007, Dr. Keller has worked as a
coinvestigator on the NIH–funded Women’s Interagency
HIV Study with Dr. Anastos, who cofounded Women’s
Equity in Access to Care and Treatment (WE-ACTx). This
effort operates in Rwanda, where Dr. Anastos and other
physicians help survivors of genocidal rape and sexual
violence obtain testing and treatment for HIV infection.
“On my first trip to Rwanda, I arrived on April 6,
2004—10 years to the day after the onset of the
country’s genocide,” says Dr. Anastos, who witnessed
the suffering and outrage of the female survivors. “The
women were HIV infected—many through genocidal
rape—and some of their perpetrators were receiving
HIV treatment in jail, while they were not.”
Dr. Anastos describes that initial weeklong trip as
“life transforming” and has since returned to Rwanda
some two dozen times. She and her WE-ACTx colleagues have helped 6,000 HIV-positive people receive
care and obtain lifesaving antiretroviral drug treatment
when indicated, and have provided HIV testing to
48,000 family and community members.
Last summer, Dr. Keller received what she calls “my
entry into global health”: her first Rwandan shipment
from Dr. Anastos, containing 80 samples of vaginal and
cervical secretions packed in dry ice. “Studies in healthy
U.S. women have shown that vaginal fluid contains
protective components that inhibit viruses and bacteria,” says Dr. Keller. “If that’s so in Rwandan women, we
may be able to develop new chemicals as microbicides
for preventing HIV/AIDS in Rwanda and other countries
where this disease causes so much devastation.”
Einstein Overseer Nathan Kahn with fourth-year medical students in Uganda
Nathan and Sandra Kahn: Helping to
Ensure a World-Class Education
for Einstein Students
“As a Modern Orthodox Jew and a graduate of
Yeshiva College, I believe we have a moral imperative to make the world a better place,” says Einstein
Overseer Nathan Kahn. “Einstein, with its strong
tradition of community service, scholarship and ethics,
embodies that imperative.”
Mr. Kahn and his wife, Sandy, have demonstrated
their deep commitment to that tradition by generously
supporting the College of Medicine, both financially
and through Mr. Kahn’s service on the Einstein Board
of Overseers. A successful entrepreneur, Nathan Kahn
has long had a keen interest in health care—a passion
that led him to become a certified paramedic, practicing in New York City.
In 2008, his role as chair of the Einstein Board’s
Student and Educational Affairs Committee took him
to Kisoro, Uganda. He made the trip at the suggestion
of Albert S. Kuperman, Ph.D., associate dean for educational affairs and founder of Einstein’s Global Health
Fellowship program, one of the first of its kind in the
United States. The purpose of the visit: to observe an
Einstein program involving fourth-year students who
assist with care for three weeks at Kisoro Hospital and
conduct a survey research project for five weeks. The
program is also open to students entering their second
year, who observe on the wards and help implement
educational programs in neighboring communities.
Mr. Kahn was impressed by what he saw. In a memo
to Dr. Kuperman, he noted the program’s “real positive
impact on the students and the local community. The
training the students are receiving seemed exceptional,” Mr. Kahn wrote. “They are learning the skills
needed to care for patients in a compassionate manner
while also acquiring skills that, in our own modern
community, may already be passing into extinction,
due to the reliance upon so many labs and tests.”
“Sandy and I believe in the critical
importance of training compassionate,
first-rate clinicians in an institution that
is also a leader in research, so we are
pleased to support Einstein.”
The Kahns’ commitment is clear. “Sandy and
I believe in the critical importance of training
compassionate, first-rate clinicians in an institution
that is also a leader in research, so we are pleased
to support Einstein,” says Mr. Kahn. “As longtime
residents of the Bronx, we’re proud to be associated
with Einstein’s work in our own community, but also
around the world.”
51
BRIDGING THE PRACTITIONER-RESEARCHER divide
Einstein’s Clinical Research Training Program
aims to identify, educate and mentor clinicians
for productive careers in research. These newly
minted clinician-scientists exemplify our core
belief: at Einstein, science is truly at the heart
of medicine.
Making the transition from medical practitioner to clinical
researcher was once an ad hoc affair. Would-be clinicianscientists learned some epidemiology here, some
statistical analysis there, leaning heavily on mentors and
colleagues for years. With persistence—and luck—they
soaked up enough knowledge to pose a good research
question, write a grant, run a clinical trial, analyze
data and publish a paper. Now, all of these skills can
be acquired in one place: Einstein’s Clinical Research
Training Program (CRTP), a two-year program leading to
a master’s degree in clinical research methods.
In this unique Einstein academic offering, “learning
is coupled with support that includes statistical consultation, database management, a clinical research center,
collaboration with laboratory scientists and mentoring,”
says Ellie Schoenbaum, M.D., director of the program
and professor of epidemiology & population health.
“The Clinical Research Training Program isn’t just a
degree program. It’s a way to transform careers.”
Launched in 1998, the CRTP also delves deeply
into grant writing and paper writing—essential skills for
clinician-scientists. The CRTP experience culminates in a
project that combines classroom learning and hands-on,
mentored research in one final thesis paper that conforms to the requirements of a peer-reviewed journal.
Successful defense of the thesis is clear proof that the
student has mastered the knowledge and skills needed
for entry into the world of clinical research.
52
Supporting Photo
Learning the Research Ropes
Einstein’s CRTP admits up to 15 scholars each year
from across the clinical spectrum. Most enrollees are
physicians, with two slots reserved for Einstein medical
students. Lately the CRTP has been accepting more
medical students (within a five-year M.D.-M.S. educational track) and more scholars from outside the field
of medicine. Current first- and second-year scholars
include, for example, four medical students and one
M.D.-Ph.D. student, plus a Ph.D. student and a dentist.
A doctor from Rwanda, Jean Claude Dusingize, M.D.,
is among this year’s enrollees. Dr. Dusingize’s mentor
is Kathy Anastos, M.D., professor of medicine and of
epidemiology & population health, who has launched
several HIV-related research projects in Rwanda (see
coverage of Dr. Anastos’ work on page 50). Upon graduation, Dr. Dusingize intends to return to his homeland
and collaborate in Dr. Anastos’ research.
Overseas outreach is an important facet of the
program: In late 2008, Dr. Schoenbaum and her colleagues presented an introductory four-week version
of the program as an intensive summer curriculum in
Mumbai, India. A second mini-CRTP is planned for
Rwanda in early 2010.
The CRTP is supported in part by a prestigious
Clinical and Translational Science Award from the
National Institutes of Health (NIH). However, this grant
“falls substantially short of meeting the needs of our
Johanna P. Daily, M.D., left, associate director of mentoring
for the Clinical Research Training Program, confers with
Ellie Schoenbaum, M.D., program director.
CRTP scholars, as well as clinical researchers who are
already on the Einstein faculty,” says Paul R. Marantz,
M.D., M.P.H., professor in the departments of epidemiology & population health and of medicine and associate dean for clinical research education, who led the
CRTP program during its first eight years. “Financial
support is critical for physician-scientists, allowing them
to reduce their hours seeing patients and focus their
time and energy on this training.” Fortunately, the
Einstein Men’s Division has helped fill this void by providing much-needed financial help for CRTP enrollees
(see page 57).
Today, the CRTP’s hundred-plus graduates can be
found throughout government, industry, health-care
systems and academe, with many grants, careerdevelopment awards and peer-reviewed papers to
their names. More than half of these graduates are
actively pursuing their research at Montefiore and
therefore retain their links to Einstein. In the pages that
follow, a representative sample of CRTP’s graduates
tell how the program has fostered their research and
enriched their careers.
53
“Little did the faculty members know that
they were signing on as mentors for life.”
Mark H. Einstein, M.D., M.S.
Mark H. Einstein, M.D., M.S.
CRTP Class of 2005
Assistant Professor of Obstetrics & Gynecology
and Women’s Health
Albert Einstein College of Medicine
Before enrolling in the CRTP, Dr. Einstein dreamed of
a career in clinical research, thinking he was a paper or
two away from becoming a full-fledged investigator. “I
had done a research project and was ready to submit it
to a journal,” he recalls. But he was quickly humbled.
“The combination of theory and practice
was golden.”
“I showed it to a senior colleague and she said it
could be published, but that I really needed serious
training in research,” he says.
Bowed but not broken, Dr. Einstein, then a new faculty member at Einstein, followed his mentor’s advice to
enroll in the CRTP. Once there, he was stunned to discover how much he didn’t know about clinical research.
“Before, research was sort of a black box,” he says.
“CRTP opened that box, not just allowing me to peek
in, but providing a detailed exploration of what questions are answerable, what kinds of study designs will
answer those questions and how to design a study.”
He particularly valued the weekly biostatistics
lectures, which are closely tied in with a computer lab.
“The combination of theory and practice was golden,”
he says. Also valuable was the course in grant writing,
he adds. “The process of grant writing was a complete
unknown for me, and probably for most people in my
54
Michelle Floris-Moore, M.D., M.S.
class. As a group, we went through the stages of conceiving a grant and constructing the various components necessary for submitting a full NIH proposal.”
Today, Dr. Einstein is the principal investigator of a
prestigious American Cancer Society Research Scholar
Grant on how epigenetic factors influence lesions
as they progress to high-grade cervical neoplasia
(a precursor to cervical cancer). In addition, he helps
lead the National Cancer Institute–sponsored
Gynecologic Oncology Group, a national clinical
trials cooperative, and is a consultant to the World
Health Organization.
“There is absolutely no way to do high-level clinical research today without additional training beyond
medical school,” he counsels. “This is not the sort of
thing that can be self-taught. I tried that.”
But the program’s value goes beyond mentoring,
she says. “The CRTP was pivotal in teaching me the
skills I needed to do clinical research: the ‘epi,’ the
‘biostats,’ the research ethics, the data analysis. The
program helped me make better use of my time as a
fellow. The program also gave me an introduction to the
clinical research community,” she continues. “It’s all too
easy to spend your fellowship isolated in a lab, focusing
just on that work and not on networking.”
Through those networks, as well as through formal
coursework, she also learned the art of grantsmanship—not just how to write and win grants, she says,
“but how to stagger your funding and make it work
for you. That’s invaluable, especially in a time of scarce
resources.” Thanks to the CRTP, she was able to secure
two grants, a K12 Mentored Clinical Research Scholar
Program Award from the NIH and a Robert Wood
Johnson Harold Amos Medical Faculty Development
Program Award.
“Those grants helped me get my first faculty
position at Einstein/Montefiore, and later in North
Carolina,” she says. “If you want to do clinical research,
you can’t get hired if you can’t bring funding.”
Today, Dr. Floris-Moore is assistant professor of
medicine at the University of North Carolina School of
Medicine at Chapel Hill. She is the principal investigator on a study of risk factors and rates of atherosclerosis among midlife HIV-infected men and women.
William N. Southern, M.D., M.S.
Michelle Floris-Moore, M.D., M.S.
CRTP Class of 2002
Assistant Professor of Medicine
University of North Carolina School of Medicine
If Dr. Floris-Moore were pressed to select the most
valuable aspect of the CRTP, she would probably say
it’s the mentoring. For her, and many other CRTP
grads, it’s a gift that keeps on giving.
“I already knew some of the faculty,” says Dr.
Floris-Moore, who was a first-year fellow in infectious
diseases at Einstein when she enrolled. “But the CRTP
allowed me to draw on the faculty in a way that would
not have been possible if I had to knock on their doors.
Little did the faculty members know that they were
signing on as mentors for life.”
CRTP Class of 2007
Assistant Professor of Medicine
Albert Einstein College of Medicine
After obtaining a career development award from the
NIH, Dr. Southern decided to enroll in the CRTP in
order “to fill in some gaps” in his knowledge about
clinical research.
“I thought I was pretty savvy as a researcher,” he
says, “but I soon realized that the CRTP would give me
the other skills I needed in epidemiology, biostatistics,
study design and decision analysis. Overall, it empowered me to do more.
“In the past, I would find a person to help me with
a deficit in my knowledge,” he continues. “Maybe I
would understand it specifically for that problem but
William N. Southern, M.D., M.S.
not on a global level. The CRTP certainly helped me to
fill in those gaps. It was a reality check.”
Upon graduation, Dr. Southern remained at
Einstein, where in short order he became director of
Hospitalist Services and associate medical director at
Weiler Hospital at Montefiore Medical Center.
“I was involved in research before,” he says. “But
now, I’m a much more collaborative member of the
“Now I’m a much more collaborative
member of the research team.”
research team. I’m not only doing the clinical research,
but working closely with the epidemiologists and basic
scientists to interpret the data and troubleshoot. The
CRTP made me an equal player on that playing field.”
In addition, the CRTP made him more competitive
in applying for grants. “The reviewers noted in their
critiques that I had received further education in clinical
research methods. It was clear that they thought it was
important,” says Dr. Southern, now an independently
funded investigator.
The program also honed his skills as a reviewer
for research journals. “Now, I’m a much more difficult
reviewer—I don’t know if that’s good or bad,” he adds
with a laugh. “But actually, I can offer more constructive criticism. And the big holes in study designs and
statistical methods are more apparent to me than they
were in the past.
“I can’t imagine that I would be where I am now
without the CRTP,” he sums up. “I feel very much
indebted to the CRTP for solidifying the skills that I had
in bits and pieces before I entered the program.”
55
Joe Verghese, M.D., B.S.
CRTP Class of 2001
Associate Professor of Neurology
Albert Einstein College of Medicine
Joe Verghese, M.D., B.S.
”There were people from various
clinical specialties, people doing
basic science, people from all
over the world.”
56
Most researchers spend an entire career without publishing in a top-tier medical journal. But just two years
after finishing Einstein’s CRTP, Dr. Verghese was the
lead author of two papers in the New England Journal
of Medicine. One reported the results of a study linking
leisure activities with a lower risk of dementia in the
elderly, while the other identified abnormal gait as a
predictor of dementia.
Dr. Verghese enrolled in the program while pursuing a clinical research fellowship in neurology at
Einstein. “I clearly had the interest to do research, but
I didn’t have the technical skills to design a study or
analyze data,” he recalls. “It was a steep learning
curve. But since I was already doing research, I could
go from the class back to my study and see how to
apply those principles. I was getting taught at both
ends. It was an ideal mix.”
Like so many others who enroll in the CRTP, Dr.
Verghese was surprised to find out how much he didn’t
know about clinical research. “I realized I was just pursuing an interesting research question without understanding the foundations on which research questions
are based,” he explains.
After the CRTP, “I felt ready to start doing research
independently,” he continues. “The learning process
doesn’t end after the two years, of course. But you
come to recognize what your strengths are and where
you should improve, and you can take that and build it
into your career plans.
“In addition, there were people from various clinical
specialties, people doing basic science, people from
all over the world—and a lot of discussion about how
to maximize your research potential and build collaborations. This enabled me to greatly expand my network
of collaborators.”
Today, Dr. Verghese is an associate professor of
neurology at Einstein and the principal investigator or
co-principal investigator of several studies on aging
and dementia funded by the NIH. “This program has
put me on the fast track academically,” he says.
The Men’s Division Research
Scholars Program
The Men’s Division Research Scholars Program
(MDRSP) is a $3 million fundraising initiative that was
launched in 2009 by the Men’s Division of Albert
Einstein College of Medicine. Its goal: to build upon
the government’s investment in Einstein by providing
the additional support needed to fund the professional
development of talented, clinically trained M.D.s who
are interested in translational research.
Each year, a small group is chosen from a pool
of 15 to 20 candidates to receive MDRSP grants.
Awardees are selected through a strict, scientific
peer-review process. Harry Shamoon, M.D., associate
dean and director of Einstein’s Institute for Clinical and
Translational Research, serves as project advisor.
“It is the dream of every physician-scientist at
Einstein to help translate breakthrough ideas from the
laboratory into innovative patient care and, ultimately,
the eradication of disease,” says Dr. Shamoon. “The
Men’s Division Research Scholars Program plays a
critical role in helping to give them that opportunity.”
On May 12, members of the Einstein Men’s Division
and special guests celebrated the division’s annual
Bronx Night at Yankee Stadium. The “Team Up with
Einstein and the Yankees” event featured guided
tours of the new stadium and launched the group’s
new fundraising initiative, the Men’s Division Research
Scholars Program.
Above left, former Mets and Yankees star Darryl
Strawberry, center, with Men’s Division executive board
members, left to right: Martin Luskin, Richard Blaser,
Stephen Karafiol, Jeffrey Fiedler, Daniel Lebensohn,
Peter Zinman and Philip Altheim.
Above right, top: Darryl Strawberry with, from left
to right, Harry Shamoon, M.D., associate dean for
clinical and translational research; Allen M. Spiegel,
M.D., the Marilyn and Stanley M. Katz Dean; and
the evening’s designated MVPs (“Most Valuable
Physicians”), Einstein faculty members Simon D.
Spivack, M.D., M.P.H., Marla J. Keller, M.D., and
Joe Verghese, M.D., B.S.
Above right, bottom: Peter Gatof, chairman of
the Men’s Division, left, with Dean Spiegel.
57
Our supporters
Science at the heart of medicine
BENEFACTORS
Dr. Gerald and Myra Dorros
F. M. Kirby Foundation
Rita and Philip Rosen
HONOR ROLL
$100,000 to $249,999
Donors who have made cumulative
contributions of $1 million or more
toward the growth and development of
Albert Einstein College of Medicine are
gratefully acknowledged as Benefactors
of the College. Their names are linked
forever with the proud history of the
College of Medicine and its medical
education and research programs.
Erica A. Drake
Lola and Saul Kramer
Judy R. and Alfred A. Rosenberg
The Ellison Medical Foundation
Tamara and Charles A. Krasne
Hedwig and Ernst Roth
American Federation for
Aging Research
Kurt and Margaret Enoch
The Joan B. Kroc Foundation
Julia and Eli L. Rousso
Ebrahim Ben Davood Eliahu
Eshaghian
Emily Fisher Landau
Louis E. and Dora Rousso
Mildred and William S. Lasdon
Florence and Irving Rubinstein
Anne and Isidore Falk
Ethel and Samuel J. LeFrak
Estate of Lila Rudin
Rose C. Falkenstein
The Rudin Family
Betty and Sheldon Feinberg
Estate of Bertram Leslie
in memory of Nathan and
Julia Levy
Albert Einstein College of Medicine
gratefully acknowledges all contributions to its medical education and
research programs from alumni, families, individuals, corporations, foundations, trusts and estates. The following
list recognizes cash gifts received
during the fiscal year ended June 30,
2009, and includes payments toward
pledges made in prior years.
Gwen and Lester Fisher
The Levitt Foundation
Martin A. and Emily L. Fisher
Benjamin J. and Anna E.
M. Levy
Our new Benefactors are in boldface
type on the list below:
Estate of Irma Adler
Abraham and Lillian Feinberg
Leo and Florence Forchheimer
Jacob P. and Estelle Lieberman
Bernice L. and Cecil Rudnick
The Family of Chella and Moise Safra
Edmond J. Safra/Republic National
Bank of New York
Anita and Jack Saltz
Linda and Earle Altman
Autism Speaks
Diane Belfer
Robert M. Beren, for the Robert
M. Beren Foundation, Inc. and
Israel Henry Beren Charitable Trust,
Robert M. Beren, Trustee
Janet Burros Memorial Foundation
Black type reflects an Einstein
alumnus or alumna
Child Welfare Fund
+ Deceased
Carol and Roger W. Einiger
Dana’s Angels Research Trust
Dr. André Aisenstadt
Leo and Julia Forchheimer
Foundation
Bernard E., Jacob J. and
Lloyd J. Alpern
The Ford Foundation
Marcia and Ronald Lissak
Lawrence and Dr. Friedericka
Steinbach Schleifer
George and Elizabeth Frankel
Frances and Herman Lopata
Helen and Irving Schneider
Estate of Charles Friedberg
Evlynne and Max M. Low
David and Irene Schwartz
Max L. and Sadie Friedman
Evelyn and Joseph I. Lubin
David S. and Ruth L. Gottesman
Rachel and Samuel H. Golding
H. Bert and Ruth Mack
The Beatrice and Samuel A. Seaver
Foundation
Lucille P. Markey Charitable Trust
Dorothy and Marty Silverman
The Gruss Lipper Family Foundation
The Honorable Walter H. Annenberg
Samuel H. Golding – Jerrold
R. Golding
Estate of Marie Markus
Nina Silverman
Ingeborg and Ira Leon Rennert
Leila and Joseph Applebaum
Horace W. Goldsmith
Patty and Lorin Silverman
Atran Foundation
The Horace W. Goldsmith
Foundation
The G. Harold and Leila Y. Mathers
Charitable Foundation
Lawrence and Dr. Friedericka+
Steinbach Schleifer
Ruth Merns
Branna and Irving Sisenwein
Sydelle and Arthur I. Meyer
The Skirball Foundation
Charles C. Bassine
The Abraham and Mildred Goldstein
Charitable Trust
Diane and Ira M. Millstein
$500,000 to $999,999
Methuselah Foundation
Florence and Theodore Baumritter
Roslyn and Leslie Goldstein
Estate of Sidney Solid
Marco and Louise Mitrani
Ellison Medical Foundation
New York Stem Cell Foundation, Inc.
Diane and Arthur Belfer
D. S. and R. H. Gottesman
Foundation
Selma and Dr. Jacques Mitrani
The Helen and Irving Spatz
Foundation
Marilyn and Stanley M. Katz
Sammy and Aviva Ofer
Benjamin and Frances Sperling
Arnold S. Penner and Madaleine
Berley
Sylvia and Robert S. Olnick
Estate of Helen Stein
Sidney and Miriam Olson
Jeffrey J. Steiner
$250,000 to $499,999
Benjamin and Susan Winter
Raymond and Bettie Haas
Arnold S. Penner and
Madaleine Berley
Estate of Margarethe I. Stern
Alpern Family Foundation
Anonymous
Marilyn C. and Jerry S. Handler
Louise and Michael Stocker
Doris Duke Charitable Foundation
Pew Charitable Trust
Estate of Irma T. Hirschl
Leo and Rachel Sussman
Laura and John J. Pomerantz
Carl C. Icahn
Siegfried and Irma Ullmann
The Horace W. Goldsmith
Foundation
The Price Family Foundation
Jack D. and Doris Weiler
Irma T. Hirschl Trust
June and Ralph Adorno
Sandra and Nathan S. Kahn
Terry and Asriel Rackow
Carl S. Bresnick and Don
A. S. Bresnick
Estates of Benjamin, Minna
and Robert A. Reeves
Evelyne and Murray Weinstock
G. Harold and Leila Y. Mathers
Charitable Foundation
Mary Kay Ash Charitable Foundation
Joan and Ernest Kalman
Kathy and Samuel G. Weinberg
Chemotherapy Foundation, Inc.
Sylvia Olnick
Jonas Ehrlich Charitable Trust
Edna S. Brodie Trust
Ida and Louis Katz
Judith and Burton P. Resnick
Entertainment Industry Foundation
The Brookdale Foundation
Marilyn and Stanley M. Katz
The Robin Hood Foundation
Betty Feinberg
Joseph and Gertrud Buchler
Mildred and Bernard H. Kayden
Sylvia and Irwin S. Chanin
W. M. Keck Foundation
Louis and Rachel Rudin
Foundation, Inc.
Gabrielle’s Angel Foundation for
Cancer Research
Rose and Wilfred P. Cohen
The Joseph P. Kennedy, Jr.
Foundation
Chella and Moise Safra
Jacob N. Glazer
The Skirball Foundation
Glenn Foundation for Medical
Research
Barbara and Philip Altheim
Linda and Earle Altman
Estate of Ruth Anixter
Mrs. Moses L. Annenberg
Joan and Lester Avnet
Frederick and Eleanore Backer
Renée E. and Robert A. Belfer
Estate of Peter Benenfeld
Estate of William Benenson
Harry H. Beren
David Berg
Margaret and Sol Berger
Harold and Muriel Block
The Breast Cancer Research
Foundation, Inc.
Leonard and Sophie Davis
Foundation
David S. and Ruth L. Gottesman
Shirley and Milton Gralla
Jeanne Gray
Rae and Henry Kalman
Lucille and Edward A. Kimmel
The Gruss Lipper Family Foundation
Estate of Gertrude E. Reicher in
memory of Eleazar and Feige
Reicher
Ingeborg and Ira Leon Rennert
Jack and Pearl Resnick
Judith and Burton P. Resnick
Charles H. Revson
Sol T. and Hortense Scheinman
Sydel and Michael Singer
Jacob D. and Bronka Weintraub
Edna and K. B. Weissman
Zygmunt and Audrey Wilf
Benjamin and Susan Winter
Elliot K. and Nancy Wolk
The Wollowick Family Foundation
David K. Evers Trust
$1,000,000 and above
The Breast Cancer Research
Foundation, Inc.
Ethel and Samuel J.+ LeFrak
F. M. Kirby Foundation
FRAXA – Fragile X Research
Foundation
Roslyn and Leslie Goldstein
Herbert P. Levine+ and Bess L.
Hormats
Robert Wood Johnson Foundation
Sandra and Nathan S. Kahn
Tamara and Charles A. Krasne
MAC AIDS Fund
McKnight Endowment Fund for
Neuroscience
The Helen and Irving Spatz
Foundation
Anonymous
$50,000 to $99,999
The Ritter Foundation
58
59
Our supporters
Science at the heart of medicine
Mary and Jay N. Goldberg
David Himelberg Foundation
Joseph F. and Clara Ford Foundation
ASM Mechanical Systems
Hannah and Edward Low
$1,000 to $4,999
Hereditary Disease Foundation
Harry and Rose Jacobs
Foundation, Inc.
The Chuck Goldman Family
Support Foundation
Dr. Peter Barland
David Luski
Dr. Marcelle L. Abell-Rosen
Linda and Peter Berley
Phyllis and William L. Mack
Dr. Emanuel M. Abrams
Joan’s Legacy: Uniting Against
Lung Cancer
Dr. Steven G. Kaali
Goodstein Memorial Trust
Marjorie Diener Blenden
Samuel Marion
Academic Pediatric Association
Joan and Ernest Kalman
Lori and Adam S. Gottbetter
Stephen N. Bobrow
Jeffrey S. Maron
Julie and Jason Ader
Susan G. Komen Breast Cancer
Foundation
Elias Karmon+
Janet and Arthur N. Hershaft
Dr. Morton D. Borg
Dr. Barbara A. McCormack
Jane Ades
David J. Klein
Jackie Harris Hochberg
Marquis Jet
Gerry Boyle
Ethel Meyer
Judy and Paul J. Konigsberg
Helen I. and Jeffrey Horowitz
Dr. Noel Nathanson
Catherine George and Frederick
R. Adler
The Mesothelioma Applied Research
Foundation, Inc.
Rosemarie Caiola
Ruth and David Levine
Anne and Robert Ivanhoe
Monique Weill Caulier Trust
Northville Industries Corp.
Drs. Ingrid and Stewart Albert
Marcia and Ronald J. Lissak
Mary and Peter S. Kalikow
Dr. Cynthia Chazotte
Dr. Stewart L. Aledort
Helen & Rita Lurie Foundation
Amy and Neil S. Katz
Dr. Joseph Citron
Samuel G. Oberlander, M.D.
Foundation
Lymphoma Research Foundation
Nancy and Jeffrey Lane
Sheila and David Cornstein
Judith and Stuart Oltchick
Amper, Politzner & Mattia, L.L.P.
Gertie F. Marx Foundation
Susan and Morris Mark
The Donaldson Organization
Roxanne and Dean Palin
Anthony Anagnostakis
Cheryl and Michael Minikes
Dr. Magdy Mikhail
Roni and Stuart Doppelt
Shirley Patent
James Anchin
NARSAD
Sydell Miller
Eastern Millwork, Inc.
Shannon and Andrew S. Penson
Lauren and Russell Anmuth
Prevent Cancer Foundation
Hilda Milton+
Dr. Mohammad A. Faisal
Iris G. and Dr. Emanuel T. Phillips
Gina J. Argento
Rett Syndrome Research Foundation
Patricia and Robert C. Patent
Mindy and Marc A. Feinberg
The Price Family Foundation
Karen J. and Dr. Ira H. Asher
Ara Parseghian Medical Research
Foundation
Rita and Philip Rosen
Pfizer, Inc.
Dr. Diane Fellows
Terry and Asriel Rackow
Doris and Myron Saranga
Joyce D. and Dr. Robert W. Finberg
Dr. Carroll A. Rayner-Paulhac
Steven E. Pegalis
Jane and Larry B. Scheinfeld
Linda and Gregory E. Fischbach
Roseman Foundation
Harriette K. Baime
Charles H. Revson Foundation
Herbert and Nell Singer Foundation
Pharmaceutical Research and
Manufacturers of America
Foundation, Inc.
Debra Thomas and David
A. Auerbach
Lynn and Dr. Allen J. Fishman
Denise and Jeff M. Rothberg
Randi and Steven Ball
Daniel E. Rothenberg
THANC Foundation, Inc.
Nancy L. and Dr. Robert J. Friedman
Amy and Howard J. Rubenstein
Marlowe and Eric Bamberger
The Alexandrine and Alexander
Sinsheimer Foundation
Sheryl and Daniel R. Tishman
Hermine Gewirtz
Dr. Nanette Santoro
Dorothy and Martin Bandier
Alexis and Oren Glick
Dana Golding Scharf and
Richard Scharf
Drs. RoseMarie Pasmantier and
Richard L. Barnett
Jules and Dr. Evelyne Schwaber
Courtney Barr
Lori and David H. Schwartz
Natalie and Brett Barth
Beatrice and Samuel H. Seaver
Foundation
Ruth Baum
Marsha and Jerry M. Seslowe
Irving P. Baumrind
Tracy and Stanley Shopkorn
Siemens Building Technologies, Inc.
Deborah and Dr. Ronald
M. Becker
Ellen and Morton F. Silver
Sam Belbina
Joel Smilow
Robert Beningson
Renée Steinberg
Dr. Judith Benstein
Taconic Investment Partners, L.L.C.
Rachel and Carl Berg
TechAir
Sandye Berger
Ann G. Tenenbaum and
Thomas H. Lee
Judith Ripka Berk
Jesselson Family
Diane and Ira M. Millstein
Dr. Harriette R. and Malcolm
D. Mogul
NephCure Foundation
Alice and Richard+ Netter, Esq.
New York Community Trust
Oxalosis and Hyperoxaluria
Foundation
The Joseph LeRoy and Ann C.
Warner Fund, Inc.
Towers League for Einstein Cancer
Research
Paula and Ira M. Resnick
Nataly and Toby G. Ritter
Marian and David Rocker
Isidor Wiesbader Foundation, Inc.
Mary Ellen Rogers
Kathy and Samuel G. Weinberg
Dr. Albert Willner
George H. Ross
Elliot K. and Nancy Wolk
Anonymous
Helen and Dr. Ronald J. Ross
Daryl and Steven Roth
Anonymous
$10,000 to $24,999
$25,000 to $49,999
Barbara and Philip Altheim
Joseph Alexander Foundation, Inc.
Hope and Marc Altheim
American Health Assistance
Foundation
Elaine and Alan Ascher
Baron Capital Group, Inc. and
Baron Capital Foundation
Austin Family Fund
Renée E. and Robert A. Belfer
Burroughs Wellcome Fund
Roula and Neil A. Clark
Leonard and Sophie
Davis Fund
Bambi and Roger Felberbaum
Harold and Isabelle Feld Charitable
Trust
Debra and Glenn R. August
Christina Baker
Viola W. Bernard Foundation, Inc.
Blank Rome, L.L.P.
James and Patricia D. Cayne
Sara Chait Memorial Foundation, Inc.
Raymond S. Cohen
Nancy and Robert Englander
Michael M. Feigin
Max Gruber Foundation
Caryl and Dr. Jay Marshall Feingold
The Marc Haas Foundation
Allison and Jason Feldman
Hedge Funds Care
Joyce and Jeffrey Fiedler
The Finkelstein Foundation, Inc.
60
The Potts Memorial Foundation
Stanley Shapiro
Jack M. Somer
Andrea Stark
Dr. Jack Stern
Marcia Hill and Guy Miller Struve
Karel Fierman Wahrsager
The Weisman Family Foundation
The Helen Hay Whitney Foundation
Wilf Family
Irene Winkelman
Dr. Z. Asher Yama
Peter E. Zinman
The Arnold P. Gold Foundation
Drs. Rene Elkin and Gary L. Goldberg
Terri and Michael W. Goldberg
Jerome Goldstein
Greg Gonzales
David Greenberg
Judy and Geoffry R. Handler
Stewart Hen
Jeffrey Henick
Jane and Michael D. Hirsch
A. Jane Jaffe
Ellen S. and Robert M. Jaffe
Elliot Kamen+
Karen and Stephen R. Karafiol
Melissa and Marc Karetsky
Erica and Michael Karsch
Dr. Nadine T. and Avram Yitzchak
Katz
$5,000 to $9,999
Bonnie and Robert Konigsberg
Ruth and Dr. Louis M. Aledort
Daniel N. Lebensohn
American Society for Dermatologic
Surgery, Inc.
Dr. Herbert J. Levin+
Thomas P. Arena
Lizzie and Jonathan Tisch
Diane and Thomas E. Tuft
Drs. Pilar Vargas and Sten
H. Vermund
Kent B. and Dr. Diane Z. Alexander
Dr. Stephen G. Baum
Dr. Staci E. Pollack and Matthew
Berke
Drs. Joanna A. Davis and Bruce M.
Berkowitz
Phyllis and Martin Berman
Dr. Paul I. Wachter
Norma and Dr. Irwin B. Bernhardt
Wade Electric, Inc.
Arlene Bernstein
Theodore and Renee Weiler
Foundation
Pamela Bernstein
Dr. Miriam Levy
Lawrence Lipman
Anonymous
Caryn and Jonathan Bilzin
Elaine and Arthur H. Bienenstock
61
Our supporters
RD Management, L.L.C. –
Jay Furman – Richard Birdoff
Dr. Elizabeth Stoner and Dr. David
Cowburn
Paula and David S. Fishman
Dan Gordon
Dr. Harold I. Jawetz
Drs. Cheryl and Mark J. Leibling
Dr. Alan R. Fleischman
Laurence L. Gottlieb
Hillary Leibowitz
Dr. Mark T. Birns
Dr. Kathryn A. Crowley
Dr. Phyllis Flomenberg
Carol S. and Dr. Allen M. Gown
Jewish Community Endowment
Foundation of Stamford
Drs. Leslie and Paul S. Blachman
Drs. Susan and Brian J. Cushin
Dr. Raja M. Flores
Jonathan H. Grabel
Carol Judelson
Michael Leonard
Dr. Andrew Lewis Blank
Dr. Barbara Allen-Dalrymple
Xavier Flouret
Brett Thomas Graham
Dr. Marc A. Kaisman
Dr. Eric Scott Lesser
Arlene and Harvey R. Blau
Dr. Jay M. Davis
Phylis Fogelson
Mrs. Adrienne Gray
Dr. Frank M. Kamer
Anne Claire Lester Foundation, Inc.
Barbara H. and James A. Block
Barbara De Portago
Linda and Daniel T. Forman
Dr. Martha S. Grayson
The Kandell Fund
Carol L. and Jerry W. Levin
Monica N. and Alan Blum
Joseph Deglomini
Dr. and Mrs. Francis A. Forte
Beverly Green
Dr. Sylvia Karasu
Herbert P. Levine Living Trust
Eric S. Blumencranz
Dr. Christine E. Blackwell and
Kenneth de Got
Janet and Dr. Israel Franco
Karin Green
Dr. Harvey Karp
Jacques M. Levy & Co., L.L.P.
Dr. Arthur M. Greenbaum
Bonnie and Bruce R. Katz
Helen and Philip Delman
Foundation, Inc.
Wendy Frank
Amy and Frank Linde
Dr. Richard S. Frankenstein
Drs. Judith and Richard Grose
Dr. Michael J. Katz
Linda and Samuel H. Lindenbaum
Judith and Herbert D. Freedman
Dr. Arthur Gross
Dr. Raananah S. Katz
Blake Lintelman
Kara K. Freedman
Gary Grossman
Robin Katz
Elfrie and Eugene Littman
Helen D. and Dr. Stephen R.
Freidberg
Alice J. and Dr. Howard S. Gruber
Florence Kaufman
Arthur L. Loeb
Dr. Joseph L. Gugliotta
Ellyn and Howard Kaye
Loehmanns Inc.
Dr. Suzanne R. Fried
Susan and John H. Gutfreund
Helene Kaye Kaplan
Dr. Timothy Loth
Drs. Richard J. and Janice L.
Friedland
Simone Gennat Haft
Kensico Capital Management Corp.
Eileen Ludwig
Jill and Bradley Hamburger
Ruth and David Kestenbaum
Harriet and Dr. Shelly Ludwig
Marilyn C. and Jerry S. Handler
Edward and Lucille Kimmel
Foundation
David and Yvonne Lurie
Rita and Dr. Lawrence I. Bonchek
Douglas Borck
Carole Boxer+
Joel Boyarsky
Ruth and Louis Brause
Dr. John M. Braver
Louise Braver
Robert A. Breakstone
Dr. Jeffrey A. Breall
Mandy and Dr. Rubin Brecher
Andrew Brettschneider
Michele and Fred Brettschneider
Dr. Julia Brody
Stacey and Matthew Bronfman
Barbara and Dr. Martin H. Brownstein
Drs. Diana E. and Gilbert Burgos
Ronald F. Burnham and Jeff Burnham
Chaya and Dr. Edward R. Burns
Patricia Calder
Boswick Cambre Family Foundation
Albert Herskovits and Korda Caplan
Linda and Arthur L. Carter
Henry Cercone
Andrew Charles
Dr. Ye-Guang Chen
Dr. Edward Chock
Lee Deutsch
Drs. Kiu Ling Tom and
Paul J. Deutsch
Shoshana and Kenneth Dichter
Drs. David W. and Rosalind
R. Dockweiler
Dr. Julie B. Dollinger
Dr. Albert Dreisinger
Maurley Miller Dupre
Edna and Dr. Roger Duvivier
Dr. Murray N. Ehrinpreis
Shelly Einhorn
Mark H. Einstein
Dr. Paul H. Elkins
Rona and Dr. Mark J. Ellenbogen
Mark Engel
Kurt and Margaret Enoch Trust
Mrs. Iris Erenstein
Mrs. Elisabetta Fabri
Dr. Stephen M. Factor
Margaret and Robert B. Fagenson
Patricia Falkenberg
Susan M. and Dr. Martin
S. Farber
CIBC World Markets Corp.
Debbie and Paul Farfel
Maureen and Marshall Cogan
Amy Feinblatt
Alyssa Cohen
Carla and Dr. Leonard N. Feinkind
Andrew B. Cohen
Dr. Sidney Fenig
Elias A. Cohen Foundation, Inc.
Richard Feuerman
Drs. Marjorie and Mark Cohen
Fundacion Filantropica Fidanque
Dr. Russell W. Cohen
Joanne and Duane Fiedler, Esq.
Dr. Steven R. Cohen and Phyllis
Cohen
Leonard Fink
Dr. Stanley Gary Cooper
Coordinated Metals, Inc.
62
Science at the heart of medicine
Arlene C. Fischer
Jacqueline Fish
Gwen and Lester Fisher
Ruth E. and Dr. Noel Friedland
Daniel S. Friedman
Robert Fromer
Frieda and Roy Furman
Bonnie and Peter Gatof
Lauren Schor Geller and Martin
Geller
Arlene and Stephen A. Genatt
Genentech
Dr. Richard I. Hansen
Dr. Linda B. Haramati
Frieda G. and Dr. Michael B. Harris
Rhonda L. and Dr. Aaron Harrison
Dr. Robert J. Harrison
Drs. Ruth Kandel and Kevan L.
Hartshorn
Shelly and Dr. Howard N. Kivell
Dr. Janice F. Klein
Dr. Michael Kligfeld
Koenig Iron Works, Inc.
Linda J. and Dr. Harold S. Koplewicz
Ellen Koppelman
Dr. Arthur Mark Kozin
Marjorie and Mark+ Gershwind
Drs. Gail E. Solomon and Harvey L.
Hecht
Jane Ellen Gerstein
Drs. David H. and Arlene M. Henick
Drs. Naomi S. and Michael
Alan Kraut
Gerstin and Associates
Dr. Mark C. Henry
Helen Kravit
Yetta and Irving Geszel
Dr. Herbert Hermele
Louis J. Kuriansky Foundation
GHP Office Realty, L.L.C.
Dr. Warren R. Heymann
Yuichiro Kuwama
Bonnie and Neil Gibgot
Dr. Steven Hindman
Dr. Shiu Y. Kwok
Rose B. and Samuel Gingold
Ruth and Dr. David M. Hirsh
Nanette Lasdon Laitman
Alicia Gitlitz
Dr. Ronald L. Hoffman
Sheila Lambert
Dr. Susan B. Glantz
Helen Horowitz
Dr. Seth Efrem Landa
Laurence Gluck
Drs. Cynthia and Suber S. Huang
Dr. Joseph Gold
Hunterspoint Steel Co.
Emily Fisher Landau and Sheldon+
Landau
Harriet and Dr. Stanford M. Goldman
Sharon Hurowitz
Amy M. and Dr. Bruce M. Goldstein
Betty G. Hut
Barbara and Dr. Allan B. Goldstein
Deanne+ and Arthur I. Indursky
Dr. Harris Goldstein
Dr. David M. Inkeles
Shulamith and Dr. Allen Goldstein
Jack Irushalmi
Dr. Stephen E. Goldstone
Jed Isaacs
James M. Goodman
Startasia and Syncerity Jacobs
Margaret E. and Bennett Goodman
Drs. Susan Leibenhaut and Joseph
E. Gootenberg
Roni Jacobson
Stewart Lane
Dr. Benjamin D. Lau
Bonnie Englebardt Lautenberg
Lawson Products, Inc.
Dr. Minh-Michael V. Le
Jody L. and Dean M. Leavitt
Lederman Family Foundation
Robin Lewis Lefcourt
Shawn Leibowitz
Elise and Martin Luskin
M Financial Group
Christine and Richard Mack
Sondra and David S. Mack
Tami and Fredric Mack
Pat and John Magliocco
Gail Maidman
The Maidman Family
Lynne and Burton J. Manning
Dr. Carl Mankowitz
Laurence Marchini III
Drs. Donna L. Vogel and David H.
Margulies
Melissa J. Markowitz
Laurence and Marlene Marton
Dr. Arthur M. Marush
Samantha Marvin
Judy M. and Dr. Marshall I. Matos
Dr. Sandra McCalla
Drs. Margaret Offerman and Russell
Marshall Medford
Bruce Meltzer
Metropolitan National Bank
Dr. B. Robert Meyer
Midtown Electric Supply Corp.
Edward Miller
Stanford Miller
63
Our supporters
Eileen Mintz
Eleanor Propp
Daphne R. and Dr. Steven Mishkin
Donna M. and Dr. Albert T. Quiery, Jr.
Joyce Misrahi
Dr. John Quinn
Mitchell Modell
Tina and Bernard D. Rabbino
Nazee and Joseph Moinian
Karin and William Rabin
Drs. Brenda Kohn and Walter J.
Molofsky
Dr. Martin S. Rapaport
Total Quality Fire &
Security Inc.
Accounteks, L.L.C.
Drs. Leticia Valeria Fulop and
Walter Soeller
Dr. William W. Tung
Sylvia and Albert J. Ades
Suzanne Turkewitz
Saks, Inc.
Beth and Dr. Philip A. Adler
Mrs. Abby Solomon
Uncle Wally’s, L.L.C.
Linda F. and Dr. Itamar Salamon
Leslie Adler
Robin Solomon
Meredith Verona
Mrs. Ali Sanders
Sharon R. and Dr. Myles Akabas
Dr. Tara A. Solomon
Stacie and David Schapiro
Dr. Thomas R. Alosco
Arthur I. Sonnenblick
Josephine and Gennaro Volgende
Charitable Trust
Stephanie and Harry Wagner
Norman and Constance Sadek
Foundation
Norma and Gordon H. Smith
Drs. Paula Marcus and
Steven Safyer
Dr. Scott D. Smoller
Fran Gold and Dr. Calvin Ackerman
Donald E. Morgan III
Drs. Cheryl L. Kunis and David M.
Rapoport
Warren Motley
Dr. Jean-Pierre Raufman
Tobie and Dr. Arthur E. Schapiro
Dr. James Moy
Dr. Avner Reggev
Dr. Joshua Schein
Sonnenschein, Nath &
Rosenthal, L.L.P.
Irma and Eddie Muller
Ann B. Terry and Dr. Michael Reich
Lisa and Gregg Schenker
Howard Sorkin
Penny and John S. Wallerstein
Carmelo Rocco Musacchia
Lynn H. and Dr. Michael J. Reichgott
Dr. Irwin Scher
James Speiser
Marla Wasserman
Nastasi and Associates, Inc.
Jessica J. Reif
Dr. James Scheuer
Dr. Gary J. Stadtmauer
Sandra and Marvin D. Wax
Joyce Neibart
Dr. Robert Riederman
Marcia and Dr. Kenneth A. Schiffer
Michell Stafman
WDF, Inc.
Drs. Alice Friedman and Gerald
Appel
Dr. Camille D. Nelson
Yael and Ben Ringel
Oscar Schlossberg
Dr. E. Richard Stanley
Webster Locksmith Company
Garth W. Appelt
Nelson Family Foundation
Jane and David H.+ Rittmaster
Lawrence I. Schneider
Dr. Andrew J. and Karen I. Stein
Jane E. and Craig J. Wehrli
Dr. Belinda C. Ark
Renee Nelson
Carol and Martin Roaman
Paola and Michael P. Schulhof
Penny and Jeffrey L. Weill
Toby Armour
Judith and Dr. Seth L. Ness
Dr. Marcia Robbins-Wilf
Dr. Robert M. Schulman
Drs. H. David and Ruth
E. Stein
Barbara J. and Dr. Mark Weinblatt
Asbestolith Manufacturing Corp.
Anita Kaskel Roe
Harvey Schulweis
Dr. J. Andrew Stein
Dr. Barbara S. and Alan Weinschel
Dr. Jacqueline Avin
Dale Roll
Dr. Victor Schuster
Betty Schwartz
Drs. Shelley Roth and Jed I.
Weissberg
Robin Aviv
Allen Rose
Joanne F. and Joseph
Stein, Jr.
Carolyn Rosen
Catherine Sosnick Schwartz
Matthew Stein
Mary B. Williams
Diane Darwish and Lance Rosen
Tricia Williams
Jennifer Baldinger
Nanette Rosenberg
Drs. Susan Cullen-Schwartz and
Benjamin D. Schwartz
Barbara E. Pollard and
Dr. Mitchell B. Stein
Dr. Denes V. Balazs
Dr. Stanley A. Schwartz
Dr. David Wisotsky
Corey Barkoff
Drs. Lisa and Burton J. Wisotsky
Donna C. and Dr. Earl Barron
Helene and Zygfryd B.+ Wolloch
Arleene F. Bearak
Dr. Joyce Guior Wolf
Beck Electric Supply
Michelle and Gerald Wolkoff
Dr. Kathleen Mary Beckingham
Dr. Donald H. Wolmer
Michael Beerman
Dr. Rodney L. Wright
Theresa Belissimo
Steven Yavers
Claudia and Kevin Bell
Drs. Hui-Li Huang and
Walter Yee
Barbara and Mitchell I. Benerofe
Carol Stone
Erica Mindes and Dr.
Kenneth Zaslav
Randi Berman
Dr. Elsa L. Stone
Lois and Martin Zelman
Jodi and Andrew Sussman
Dr. Arthur Zimmerman
Drs. Nancy and Ira Sussman
Alexandra and Dr. Jonathan Zizmor
Sally Siegel
Leah and Steven Swarzman
Christina Zunker and Jim Donnell
Stephen Silberstang
Dr. Sheila Tanenbaum
Michelle and Andrew Silberstein
Dr. Marie-Ange and Philippe Tardieu
Adrianne and William Silver
Dr. Sonya S. Noh
Drs. Faranak Daravi and Farshad J.
Nosratian
Lisa and Ciaran O’Kelly
Dr. Joseph J. Okon
Dr. Edward T. O’Neil
John O’Neill
Carole and Mitchell Wm. Ostrove
Outdoor Installations, L.L.C.
Eli Oxenhorn
Palin Family Foundation
Pamela Pantzer
The Par Group
+
Dr. Seligman Rosenberg
Drs. Dorothy and Alvin Rosenfeld
Dr. Carl E. Rosenkilde
Juliet Rosenthal Foundation, Inc.
Pat and John Rosenwald
Alon Rosin
Barbara and Allen Ross
Lillian and Dr. Barry Paul
Nina and Ivan Ross
Bret B. Pearlman
Dr. Jesse Roth
Marion Pearlman
Dr. Jonathan Alan Rothblatt
Helen Peck
Dr. Anamaria Perez
Steven J. and Robin Rotter Family
Foundation
Claire Perlman
Julia Rousso
Dr. Andre A. Persaud
Lawrence Ruben, Esq.
Dr. Victoria and John J. Persky
James Rubin
Kristin K. and Damian J. Pieper
Dr. Mark I. Rubin
Pieper New York Multistate Bar
Review, Ltd.
Ruthellen and Dr. Marc R. Rubin
Drs. Ingrid and David Pisetsky
Ruby Diamond Foundation
P. J. Mechanical Corp.
Dr. Jeffrey C. Rudikoff
Geri Pollack
Dr. Craig P. Russo
Stacy and Douglas Polley
Mary Sachs Trust
Scott Prince
64
Science at the heart of medicine
Gail C. and Charles Rubinger
Marion Scotto
Sheila J. and Dr. Michael
E. Sekela
Select Equity Group, Inc.
Aline Shapiro
Blanche and Romie Shapiro
Dr. Melvin D. Shay
Mrs. Stacey Sheinbaum
Dr. Ian M. Shivack
Dr. Sandra E. and Jed M. Shivers
Jerry Shore
Arlene Farkas and H.
Kenneth Sidel
Joel Steinberg
Shari M. Stenzler
Drs. Joseph Furgiuele and Frances
Stern
Dr. Penny M. Stern
Dr. Robert C. Stern
Shai Z. Stern
Paula and Michael Stoler
Dr. Andrew A. Stolz
Dr. Ruth Stolz
David Walerstein
Wendy Alper
Dr. Joan C. Amatniek
Dr. Kathryn Anastos
Marie F. Robert and Dr. Warren
Andiman
Brenda Axelrod
Deborah Berger
Marc Bern
Amelia and Richard A. Bernstein
Julie Bernstein
Dr. Peter S. Bernstein
Tamara Bernstein
Drs. Selma and Jerome Targovnik
$500 to $999
Ruth A. and Dr. Chester M.
Berschling
Dr. Douglas Simon
Rochelle and Abraham Tennenbaum
Rocco Abbate
Randi and Marc Berson
Neil Simon
Barbara D. Tober
Carol Abrams
Wendy Biderman
Dr. Robert M. Simon
Glenn and Lynn Tobias Family
Foundation, Inc.
Robert E. Abrams
Annette Bierfriend
Dr. David H. Abramson
Debra and Leon Black
Dr. Eileen A. Toolin
Jay Abramson
Richard D. Blaser
Mary Ann Siskind
Bruce Smith
Dr. Gunter Blobel
65
Our supporters
Miriam and Dr. Jeffrey Block
Ruth A. and Murray Drucker
Judie and Howard L. Ganek
Stephen Hanson
Carol and Allen Klein
Ellen M. Lieb
Susan Bloom
Suzanne and Dr. Thomas
P. Ducker
Jill S. Garner
Jerry Harnik
Jacquelyn L. Klein
Dr. Arnold Lieber
Dr. Sarah K. Garrison
Nicki and J. Ira Harris
Dr. Phyllis H. Klein
Dr. Harry J. Lieman
Mary Duff
Merilyn Geisberg
Shelley D. and Gilbert Harrison
Dr. Andrew R. Klipper
Dr. Kenneth M. Lipman
Roberta Bogen
Katherine and Dr. Sheldon Eisenman
Betsy Hart
Richard E. Kobrin
Kim and Greg Lippmann
Lisa Borodkin
Judith and Dr. Joel W. Eisner
Dr. Linda Weinman Wolf and
Alexander J. Gelber
Lynne G. and Caleb D. Koeppel
Holly Lipton
William B. Bram
Dr. Howard B. Eison
James B. Gerstein
Madeline and
Dr. Sidney Hart
Allison Bandier Koffman
Tara Lipton
Sandy Zabar and Dr. Ira D. Breite
Marjorie and Robert B. Emden
Dr. Michael D. Geschwind
Kristy and Robert Harteveldt
Andrew Kofman
Jan G. and Dr. Jerome M. Loew
Dr. Albert L. Brooks
Alicia and Dr. Mark A. Erlich
Dr. Gary Lombardi
Dinah A. Evan
Judith B. and Dr. Stephen
P. Haveson
Faith Kates Kogan
Joanne Bross
Bernard S. and Sarah M. Gewirz
Foundation Inc.
Sandra F. Heine
Ilyssa Londa
Elena H. Ezratty
Alma L. and Joseph B. Gildenhorn
Dr. Patrick T. Konitzer
Freda and Dr. Kevin R. Brown
Steve Fallek
Gail and Arnold Ginsburg
Dr. Eugene Heller
Dr. Barry London
Jennifer Brown
Meredith J. and James David
Kornreich
Charles F. Brush
Marilyn J. and Dr. Arthur N. Feinberg
Annette Gladstein
Jill Heller
Barbara and Dr. Donald P. Kotler
Sondra and Norman Feinberg
Ruth L. and Dr. Todd D. Heller
Dr. Phyllis E. Kozarsky
Dr. Eugene A. Burke, Jr.
Drs. Eileen Wolf and James Feldman
Daniel Birger and Dr.
Ellen Glass
Donna Low
Dr. Carol Burg
Pamela S. and Jonathan S. Henes
Kristine S. and Dr. Robert
S. Lupi
Candace Bushnell
Dr. Laura Feldman
Gloria Glatt
Fay and Dr. Harvey N. Kranzler
Samuel J.+ and Ronnie Heyman
Brian Glazer
Jesse Krasnow
Linda and Harry Macklowe
Dr. Glenn S. Hirsch
Glazer Capital Management
Drs. Sherry Lynne and Robert Krausz
Arielle Madover
Brad S. Gluck
Harriet G. and Dr. Fred C.
Hirschenfang
Dr. Stephen M. Kreitzer
Kevin Magid
Dr. Linda Gochfeld
Burton D. Hoffman
Sue Parilla and Dr. Theodore G.
Krontiris
Dr. Jacqueline Jaswant Mahal
Eleanor I. and Dr. Lester R. Goldberg
Wandy Yeap Hoh
Carol Kushnick
Dr. Suanne L. and Stephan
Mallenbaum
Irving Goldblum
Jane B. and Dr. Robert Kutnick
Lori Margolis
Lisa Golden
Drs. Shella Farooki and James
J. Homsy
Leslie Mathias
Tracie Golding
Dr. Susan Levine Hooker
Alyson and Kenny Lane
Dr. Susan B. Horwitz
Barbara M. and Richard S. Lane, Esq.
Mark Martinez
Ali Goldstein
Cheryl R. and Dr. William Hurwitz
Dr. Sandra Masur
Eve H. and Dr. Joel A. Goldstein
Drs. Liise-anne Pirofski and
Charles Langs
Dr. Marion Zucker Goldstein
Drs. Suguru and Avlin B. Imaeda
Natalie Lansburgh
Patricia Matlin
Drs. Wendy and Richard
M. Bochner
Millicent Calicchio
Marjorie and Dr. Howard J. Feldman
Louise and Vincent Camuto
Serafin Fernandez, Sr.
Gillian Salama Caro
Myron and Ginger Feuer
Marc Ceruto
Joseph B. Field
Jean and Dr. Leon Chameides
Lisa Fields
Vera and Philip L. Chapman
Dr. Albert H. Fine
Margaret and Dr. Chaim Charytan
Norman Fink
Drs. Wei Li and Mei Chen
Robert H. Finkelstein
Dr. Patricia Y. Love
Dr. Harvey R. Chertoff
Dr. Stanley I. Fisch
Dr. Peter Chiraseveenuprapund
Shirley and Dr. Howard Chung
Michelle D. and Dr. Jeffrey
D. Fisher
Maureen A. Cogan
Dr. Norman Fleischer
Mrs. Karen Goodman
Jamie Jacobson
Bennett H. Last
Elinor Wohl Cohen
Drs. Susan L. Eder and Jonathan
Flescher
Rona and Lee H. Javitch
Elizabeth Mazolis
Marilyn Gordon
Andrew Laufer
Noelle Kahan
Greg McCarthy
Gail K. and Dr. Kenneth I. Gottlieb
Teresa Launi
Danielle Grant
Jessica Kalimian
Eric Medow
Nancy and Dr. Charles A. Forscher
Rachel Laxer
Hana and Allan Green
Dr. Eric D. Kanter
Carol Mehler
Dr. Fabius Fox
Dr. Stephen H. Lazar
Dr. Leonard N. Green
Adrienne S. Kapel
Julie Menin
Karen Fraley
Dr. Andrew Lazris
Cheryl Lefkovitz
Rochelle Kaplan
Dr. Peter B. Milburn
Doris L. Frank
Dr. Stephanie A. and Stephen J.
Green
Jackie B. Kaplan
Kim and Evan Meyers
Bruce Frank
Susan Carmel Lehrman
Dorie B. and Dr. Bernard Greenberg
Dr. Stephen B. Kardon
Glenn Miller
Susan Frankel
Niloufar and Dr. Rudolph L. Leibel
Ellen J. and Dr. Stephen Greenberg
Loryn Cohen Kass
Mr. and Mrs. Martin H. Miller
Dr. Pamela Gottesman Freedman
Ann R. Levi
Roberta Greenberg
Erica Katz
Dr. Nava and Gideon J. Miller
Drs. David Tange and Mary Jo
Freeman
Betty Levin
Dr. Robert Grenitz
Joan B. Kaufman
Dr. Arthur E. Millman
Dr. Ilissa Joy Levine
Eric Friedland
Amy Lauren Gross
Dr. Patricia Kavanagh
Jamie and David Mitchell
Tammy Levine
Carole H. Friedman
Dorothy and Dr. Kenneth Grossman
Dr. Paraic A. Kenny
Manish Mittal
Dr. Andrew Levitas
Melanie Friedman
Madeleine and Dr. Edward Grossman
Alice and Ira Kent
Dr. Stewart L. Mones
Lynne L. and Dr. Sidney Levitsky
Rand Frohlich
Perry Haberman
Dr. Mark B. Kerner
Aela Morgan
Levitt-Fuirst Associates, Ltd.
Victoria Moran Furman
Amie Murstein Hadden
Dr. Amy E. and Todd Kesselman
Jeff Moses
H. Irwin Levy
Dr. Ann Furtado
John W. Hadden II
James G. King
Dr. Solomon L. Moshé
Susan and Alan Levy
Vanessa Gad
Linda Haft
Susan Kingsolver
Aileen Murstein
Ellie Libby
Inga Galiullina
Natalie M. and Donald Handelman
Cara Klein
Dr. Richard L. Myerowitz
Lisa Licht
Dr. Jeremy P. Nahum
Lyor Cohen
Maya Cohen
Lisa and Dr. Joel Confino
Podi Constentiner
Kim Cornell
Natasha S. Cornstein
Dr. Nereida Correa
Dr. Jeffrey Stephen Crespin
Dr. Edward C. Croen
Golda and Dr. Sheldon J. Davidson
Marilyn and Richard Davimos
Dr. Peter J. Davis
Dr. George Dickstein
Katarina Dimich
Drs. Mary M. Ross and Eric
G. Dolen
Dr. Jacqueline L. Downs
66
Science at the heart of medicine
Elliot I. Matlin
67
Our supporters
Belkis Nasser
Steven Post
Dr. John P. Sanchez
Melissa H. Smith
Venus Construction, Ltd.
ESTATES AND TRUSTS
Julie H. and Dr. Henry P. Nathan
Power Adjustment Group, L.L.C.
Mara Sandler
Snyder and Snyder, L.L.P.
Allison Veronis
Stuart Nayman
Mary Powers
Charles Sanlso
Eugene and Dr. Sara Vogel
Ellen Meyers and Dr. Barry N.
Neeland
Jacqueline and Bruce Prescott
Dr. Joseph A. Santiago
Barbara L. and Dr. Sidney
H. Sobel
Alix Prince
Denise Saul
Felicia Warshawsky
Valerie Neustadt
Dr. Alec D. Pruchnicki
Joan and Stuart Schapiro
Dale F. and Dr. Stephen M.
Sonnenberg
Gifts from the estates and trusts listed
below were received during the period
from July 1, 2008, to June 30, 2009. We
greatly appreciate their legacy of caring
and support.
Dorothy Neustadter
Prudential Financial
Dr. Henry A. Schechter
Dr. Hoa N. Nguyen
Susan Bender Scheer
Dr. Noelle B. Nielsen
Penny and Dr. Dominick
P. Purpura
Alissa Nierenberg
Richard Pyles
Karen Blumenfeld and Dr. Andrew
A. Nierenberg
Nancy N. Radin-Tarnoff
Linda R. and Dr. Allan
J. Scher
Cathy L. and Dr. Neal E. Rakov
Anita L. and Dr. David Schick
Satoko Miyake and Aaron Nir
Dr. Elyse Sussman and Mark Ramler
Dr. Abraham T. Schneider
Dr. Donald A. Nisbett
Dr. Helen M. Ranney
Charlotte Schoenfeld
Lynda Nitabach
Nancy Shaw and Walter Raquet
Brigitte Schore
Northbrook Contracting
Corp.
Bernette and Dr. Allan M. Rashba
Edith A. and Marvin H. Schur
Joan and Dr. Mark D. Reiss
Schwartz & Company, L.L.P.
Olga E. and William Reynolds
Mr. and Mrs. Theodore Schwartz
Andrew Richard
Peter W. Schweitzer
Michael Richman
Marion and Dr. Robert C. Richter
Drs. Stephanie Bernstein and Franklin
D. Segall
Dr. Gary T. Robinson
Sharon Seibold
Barbara Rodolitz
Seiden & Schein, P.C.
Maxine Rose
Joan Serchuck
Sandra Rose
Jane Shalam
Julie Rosefay
Dr. Ellyn P. Shander
Rona and Dr. Michael H. Rosen
Andrew Shapiro
Zachary Rosenbaum
Drs. Leonard Z. and Deanne Shapiro
Drs. Andrea J. Needleman and Mark
S. Rosenberg
Dr. Vicki D. and Dr. Glen David
Shapiro
Dr. Jehangir Patel
Henrietta K. and Dr. Henry
Rosenberg
Debra D. Peltz
Andrew M. Peretz
Dr. Jeffrey Steven Novak
Dr. Ira S. Novich
Ilana Nowick
Nancy and Harold Oelbaum
Livia Schenker
Marcy and Dr. Alan Spertus
Harvey Spevak
Karen and Paul Spiegel
Dr. Theta I. Spielman
Salvatore Lo Bianco and Dr. Claire
Spininger
Cherie Neger Stahl
Dr. Jeffrey A. Stahl
The Steel Partners Foundation
Dr. Stephen Stein
Susan B. Steinhardt
Robina J. and Dr. Jerry
O. Stern
Paula and Michael Stoler
Sidney Stoller
Allison Wallach
Sandra and Stanford S. Warshawsky
Cynthia Wasserberger
Sandra K. Wasserman
Estate of André Aisenstadt
Susan Waterfall
Estate of David B. and Rosalind
W. Alcott
Karen S. and Edwin Weisberg
Frederick and Eleanor Backer
Carol and Herman H. Weiss
Estate of Albert A. Berger
Susan Weiss
Estate of Elsie L. Bernstein
Steven J. Weissbluth
Robert Blauner Testamentary Trust
Dr. Jerry Weissman
Estate of Rebecca Davis
Tanya and Harvey Weitz
Estate of Manny Hilfman
Drs. Sylvia S. and Howard
K. Welsh
Estate of Estelle Knapp
Barbara K. and Dr. Stephen A.
Wertheimer
Estate of Lony Lobner
Ilene Wetanson
Dr. Roger M. Wint
Estate of Bertram Leslie
Estate of Marie Markus
Estate of Edna Rabin
Dr. Harley M. Wishner
Estate of Gertrude E. Reicher
in Memory of Eleazar and
Feige Reicher
Jill Wolf
Estate of Judith R. Rosenberg
Rochelle G. and Dr. Mitchel L. Wolf
Estate of Adele Rothenberg
Leila Straus
Myrna R. and Dr. Stuart
B. Wollman
Estate of Helena Barkmann Schramm
Helen Evans Struve
Dr. Pauline Woo
Hugo S. Subotovsky
Evan Richard Wuhl
Estates of Dorothy and Sol Smolen
Dr. Diana K. Sun
Drs. Joel and Eileen Yager
Ramy Sharp
Ruth L. Suzman
Janice G. and Dr. David M. Yamins
Amy S. and Dr. Michael J. Shaw
Gloria and Seymour Svirsky
Alan Yukuboff
Joan Rosenberg
Joanne and Dr. Spencer Shaw
Jeffrey Tabak
Julie N. and Scott E. Zelnick
Maura and Leonard Shaykin
Dr. Joon Kheng Tan
Lois and Bruce Zenkel
Laura Perlmutter
Miriam and Dr. Howard W.
Rosenblum
Lauren Lazare Shell
Dr. Naomi P. and Andrew Taylor
Laura Zeppieri
Dr. Lilli M. Petruzzelli
Dr. Martin S. Roshco
Holly Sherr
Jordan Teramo
Elisa and Brian L. Zied
Elaine and Charles I. Petschek
Susan and Jon Rotenstreich
Dr. Gilda L. Sherwin
Renate Zimet
Dr. and Mrs. Robert Y. Pick
Jeanine Rush
Vivian and Dr. Yale Shulman
Dr. Danielle C. Moller-Thau and Dr.
Steven A. Thau
Terri Pitts
Thomas A. and Georgina
T. Russo
Mitchell Darrow Silber
Dr. Shaindy Joyce and
Dr. Mayer I. Rydzinski
John Silverman
Carole Olshan
John O’Neill
Felice B. Oper
Dr. Stuart B. Orenstein
Diane R. and Dr. Walter A. Orenstein
Myra L. Freed and Dr. Seth J. Orlow
Carol D. and Dr. Lewis A. Osofsky
Alan F. Pacella
Dr. Steven W. Pappas
Shelley Lieff and Jeffrey M. Parker
Linda Plattus
Dr. Susana C. Poliak
Leon Pollack
Mona M. and Dr. Murray
M. Pollack
Louise and Dr. Alan Polsky
+
Amanda Poses
Saretha and Dr. James B.
Post IV
68
Science at the heart of medicine
Wendy Erin Sacks
Dr. Lauren E. Kaplan-Sagal and
Douglas Sagal
Felicia Sale
Joan Saltz
Cynthia Samwick
Natasha Silver
Dr. Joel W. Silverstein
Liana C. Silverstein
Ashu Singh
Dr. Samuel A. Skootsky
Dr. Arthur I. Skoultchi
Linda Jane Smith
Dr. Israel M. Stein
Dr. Joel Stein
Melvin Stock
Eileen and Dr. Maurice Strahlberg
Jane and Peter Strasser
Bernice Thomas
Claire Tieger
Kerri Topping
Helen and Nathaniel Wisch
Drs. Susan and Edward Zoltan
Caryn and Jeff Zucker
Estate of Charles Sender
Estate of Larry Stock
Estate of Ruth Turberg
Estate of Claire Wagner
Anonymous
PLEASE NOTE:
Every effort has been made to
ensure the accuracy of the information
provided. We very much regret
any errors or omissions that may
nevertheless have occurred.
Barbara Zuckerman
Dr. Christopher M. Tortora
Melanie and Jeffrey H. Tucker
Adam Tuckman
Commy and Dr. Okoro
C. Ukpabi
Benita K. and Ronald L. Unger
Dr. Arnold Valenson
69
Financial Summary
Board of Overseers
Einstein Adjusts to Difficult Economic Times,
But Key Indicators Are Positive
CHAIRPERSON
As the College of Medicine expected, the economic recession is causing income from investments to decline.
During the fiscal years (FY) 2009–13, Einstein will compensate for these revenue declines by cutting its nonacademic expenses. By saving on energy costs, postponing capital projects and reducing information technology
expenses, Einstein is reducing total anticipated expenditures for the coming five years by about $100 million,
beginning with a $20 million saving from the approved budget in FY2009 (July 2008–June 2009).
Meanwhile, the College of Medicine has continued to follow its strategic plan by recruiting high-quality
faculty and improving its research infrastructure. Two positive indicators are the continued growth in gifts and
payments for existing pledges and increase in NIH grant awards for the just-ended federal FY2009 (see graphs
below). Despite the difficult economy, new cash gifts and payments on pledges rose to their highest level,
totaling $38.28 million (Figure 1). Similarly, NIH awards for federal FY2009 increased from $132.1 million in
FY2008 to $154.9 million in FY2009 (Figure 2).
CHAIRPERSONS EMERITI
Dr. Ruth L. Gottesman*
CHAIRPERSON
EXECUTIVE COMMITTEE
Michael F. Price*
VICE CHAIRPERSONS
Zygmunt Wilf*
Elliot K. Wolk*
Revenue Trends 2000 – 2009
Figure 1: Cash Gifts
Figure 2: National Institutes of Health Awards
45
180
$38.3
$154.9
TREASURER
Roger W. Einiger*
40
160
35
140
Secretary
30
120
Daniel R. Tishman*
$’s in millions
$’s in millions
Burton P. Resnick*
Robert A. Belfer*
Ira M. Millstein*
25
20
15
100
80
10
40
5
20
0
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
NIH budget doubles
NIH budget flat
60
0
2000
2001
2002
2003
2004
2005
2006
2007
Einstein Profile
Affiliated Hospitals
M.D. students: 625
Montefiore Medical Center
Ph.D. students: 337
Beth Israel Medical Center
Faculty: 2,775
North Shore–Long Island Jewish Health System
Applicants to Class of 2013: 7,148
Bronx–Lebanon Hospital Center
Students in Class of 2013: 183
Jacobi Medical Center
NIH
receives
stimulus
funds
2008
Philip Altheim*
Linda Altman*
Irving P. Baumrind
Diane Belfer
Renée E. Belfer
Robert A. Bernhard
Roger Blumencranz
John D. Cohen
Dr. Gerald Dorros, ’68
Betty Feinberg
Peter Gatof
Jay N. Goldberg
Roslyn Goldstein*
Dr. Stephen Goldstone, ’79
Arthur Hershaft*
Morton P. Hyman
Michael G. Jesselson
Richard M. Joel
Nathan Kahn*
Ernest Kalman
Marilyn Katz
Stanley M. Katz*
Paul J. Konigsberg*
Dr. Henry Kressel
Dr. Ira Kukin
Hirschell E. Levine
Dr. Evelyn Lipper, ’71
Ronald J. Lissak*
Harvey Newman
Sylvia Olnick
Arnold S. Penner
Joel I. Picket
Rita Rosen
Howard J. Rubenstein
Larry B. Scheinfeld
Dr. Lawrence Scherr
Harvey Schulweis
David A. Tanner
Louis R. Tomson
Kathy Weinberg
Samuel G. Weinberg*
Benjamin Winter
LIFE OVERSEER
Philip Rosen
HONORARY OVERSEERS
Joan K. Eigen
Jerry S. Handler
Charles A. Krasne
Emily Fisher Landau
John J. Pomerantz
Toby G. Ritter
*Executive Committee
2009
Residency programs offered: 150
Postdoctoral research fellows: 380
Major research centers funded by NIH: 5
Physicians in training at Einstein and
affiliated hospitals: 2,500
Einstein alumni: more than 8,500
70
71
71
Albert Einstein College of Medicine
o f y e s h i va u n i v e r s i t y
Science at the heart of medicine
Albert Einstein College of Medicine
of Yeshiva University
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Bronx, NY 10461
www.einstein.yu.edu
Philip and Rita Rosen Department
of Communications and Public Affairs
Department of Institutional Advancement
For information on opportunities for giving:
718.430.2412
fax 718.430.8929
10%
72
Fly UP